{ "class": "GraphLinksModel",
  "nodeDataArray": [
{"submap_nodes_id":1083, "submap_id":2, "object_id":1, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Basic Science Research", "label_name":"Basic Science Research", "group_name":"Basic Science Research", "reference_synonym":"Basic Research", "identifier_CUI":"C0681833", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCI", "Level_II_Description":"A type of study designed to examine the basic mechanism of action (e.g., physiology, biomechanics) of an intervention. (ClinicalTrials.gov)", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCIt", "Alt_Identifier_CUI":"NCIt", "Level_II_Alt_Description":"Fundamental research designed to obtain or increase general scientific knowledge.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"statesforbiomed.org", "Alt_Description2":"Research conducted to increase the base knowledge and understanding of the physical, chemical, and functional mechanisms of life processes and disease. It is fundamental and not directed to solving any particular biomedical problem in humans or animals. This type of research often involves observing, describing, measuring, and experimental manipulation and provides the building blocks upon which the other types of research (applied and clinical) are based. A basic researcher seeks to add to the store of knowledge about how living things work. A basic researcherâ€™s experiments add pieces to the immensely complex puzzles of life.", "Alt_URL2":"http://statesforbiomed.org/education/background-on-biomedical-research/biomedical-research-definitions/", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":1, "parent":116, "color":"#d32f2f", "nodeLocContent":[ {"ObjectId":1, "name":"Basic Science Research", "display_name":"", "uri":"https://ncats.nih.gov", "uri_display_name":"ncats website", "description":"Basic Science Research description", "poc_first_name":"TestFirst", "poc_last_name":"TestLast", "poc_email":"test@test.com", "street_address":"5312 Connecticut Avenue Northwest", "city":"Washington", "state":"DC", "zip":"20015", "lat":38.9593155, "lng":-77.0728605} ], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1084, "submap_id":2, "object_id":3, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":1, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Biomedical Informatics", "label_name":"Biomedical Informatics", "group_name":"Basic Science Research", "reference_synonym":"Bioinformatics", "identifier_CUI":"C1140694", "NCI_thesaurus_code":null, "semantic_type":"Biomedical Occupation or Discipline", "sematic_type_code":"T091", "Level_II_Source":"NCI", "Level_II_Description":"The science of using computers, databases, and math to organize and analyze large amounts of biological, medical, and health information. Information may come from many sources, including patient statistics, tissue specimens, genetics research, and clinical trials.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"The science of using computers, databases, and math to organize and analyze large amounts of biological, medical, and health information. Information may come from many sources, including patient statistics, tissue specimens, genetics research, and clinical trials.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Biomedical informatics is the application of computer science and information technology to the field of molecular biology.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/bioinformatics", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":3, "parent":1, "color":"#d32f2f", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1085, "submap_id":2, "object_id":4, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":1, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Hypothesis Generation", "label_name":"Hypothesis Generation", "group_name":"Basic Science Research", "reference_synonym":"Hypothesis", "identifier_CUI":"C1512571", "NCI_thesaurus_code":null, "semantic_type":"Idea or Concept; T078", "sematic_type_code":"T078", "Level_II_Source":"NCI", "Level_II_Description":"A tentative proposal made to explain certain observations or facts that requires further investigation to be verified.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"A tentative proposal made to explain certain observations or facts that requires further investigation to be verified.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"A hypothesis is a proposed explanation for a phenomenon. Observations are used to form hypotheses, which are then tested during experimentation.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/hypothesis", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":4, "parent":1, "color":"#d32f2f", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1086, "submap_id":2, "object_id":5, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":1, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Disease Pathophysiology", "label_name":"Disease Pathophysiology", "group_name":"Basic Science Research", "reference_synonym":"physio pathological", "identifier_CUI":"C0031847", "NCI_thesaurus_code":null, "semantic_type":"Functional Concept; T169", "sematic_type_code":"T169", "Level_II_Source":"MSH", "Level_II_Description":"Used with organs and diseases for disordered function in disease states.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Disease pathophysiology is the study of how disease alters the functions of cells, organs, organ systems, and how these changes in turn affect the entire body.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/pathophysiology", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":5, "parent":1, "color":"#d32f2f", "nodeLocContent":[ {"ObjectId":5, "name":"disease 223999", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":null, "poc_last_name":null, "poc_email":null, "street_address":"883 Boylston Street", "city":"Boston", "state":"MA", "zip":"02116", "lat":42.3486744, "lng":-71.0836219},{"ObjectId":5, "name":"Disease Pathophysiology", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"test", "poc_last_name":"test", "poc_email":"teset@getrs.com", "street_address":"9000 International Drive", "city":"Orlando", "state":"FL", "zip":"32819", "lat":28.4338056, "lng":-81.4728696} ], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1087, "submap_id":2, "object_id":6, "function":"Document", "sub_function":"Database Reference", "relationship":"Database Clinical", "submap_node_parent_id":1, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Therapeutic Targets", "label_name":"Therapeutic Targets", "group_name":"Basic Science Research", "reference_synonym":"biological target", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Molecular Function; T044", "sematic_type_code":"T044", "Level_II_Source":"AGM Glossary", "Level_II_Description":"A macromolecule or a set of macromolecules in a biochemical pathway that is responsible for the disease pathology.", "Level_II_Link":"https://www.ncbi.nlm.nih.gov/books/NBK92002/", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Therapeutic targets are molecular sites for therapeutic intervention. By altering the expression or function of therapeutic targets using drugs or other therapies, researchers hope to either cure the underlying cause of a disorder or relieve disease symptoms.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/targets", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":6, "parent":1, "color":"#d32f2f", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1088, "submap_id":2, "object_id":7, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":3, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Data Mining", "label_name":"Data Mining", "group_name":"Basic Science Research", "reference_synonym":"Data Mining", "identifier_CUI":"C1328866", "NCI_thesaurus_code":null, "semantic_type":"Machine Activity; T066", "sematic_type_code":"T066", "Level_II_Source":"MSH", "Level_II_Description":"Use of sophisticated analysis tools to sort through, organize, examine, and combine large sets of information.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"MSH", "Alt_Identifier_CUI":"MSH", "Level_II_Alt_Description":"Use of sophisticated analysis tools to sort through, organize, examine, and combine large sets of information.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":7, "parent":3, "color":"#d32f2f", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1089, "submap_id":2, "object_id":8, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":5, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Cell Lines", "label_name":"Cell Lines", "group_name":"Basic Science Research", "reference_synonym":null, "identifier_CUI":"C0007600", "NCI_thesaurus_code":null, "semantic_type":"Cell; T025", "sematic_type_code":"T025", "Level_II_Source":"NCI", "Level_II_Description":"A permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":8, "parent":5, "color":"#d32f2f", "nodeLocContent":[ {"ObjectId":8, "name":"cell lines", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"erw", "poc_last_name":"wer", "poc_email":"wer@sdf.com", "street_address":"2341 2nd Avenue", "city":"New York", "state":"NY", "zip":"10035", "lat":40.799781, "lng":-73.936107} ], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1090, "submap_id":2, "object_id":9, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":5, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Animal Models", "label_name":"Animal Models", "group_name":"Basic Science Research", "reference_synonym":"Animal Model", "identifier_CUI":"C0599779", "NCI_thesaurus_code":null, "semantic_type":"Animal; T008", "sematic_type_code":"T008", "Level_II_Source":"NCIÂ ", "Level_II_Description":"An animal that is amenable to experimentation and whose physiological or pathologic mechanisms are sufficiently similar to those of a human for the animal to serve as a model.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"MSH", "Alt_Identifier_CUI":"MSH", "Level_II_Alt_Description":"Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Animal models are organisms, often mice or rats, that have been engineered to reproduce the physical or molecular changes that occur during the course of a disease in humans. These models are used to study the biology of the disease, including the genetics and the cellular or molecular pathways involved in the disease. Animal models also have a critical role in developing and testing new therapies before they are tested in humans.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/animal_models", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":9, "parent":5, "color":"#d32f2f", "nodeLocContent":[ {"ObjectId":9, "name":"Animal 223", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"test", "poc_last_name":"tet", "poc_email":"test@se.com", "street_address":"787-793 Massachusetts Avenue", "city":"Arlington", "state":"MA", "zip":"02476", "lat":42.416692, "lng":-71.158408},{"ObjectId":9, "name":"Animal Models", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":null, "poc_last_name":null, "poc_email":null, "street_address":"2341 2nd Avenue", "city":"New York", "state":"NY", "zip":"10035", "lat":40.799781, "lng":-73.936107} ], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1091, "submap_id":2, "object_id":10, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":5, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Molecular Pathway", "label_name":"Molecular Pathways", "group_name":"Basic Science Research", "reference_synonym":"Biochemical pathway", "identifier_CUI":"C1704259", "NCI_thesaurus_code":null, "semantic_type":"Molecular Function; T044", "sematic_type_code":"T044", "Level_II_Source":"NCI", "Level_II_Description":"A series of actions among molecules in a cell that leads to a certain end point or cell function.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"A series of actions among molecules in a cell that leads to a certain end point or cell function.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"A molecular pathway is a series of interactions that occurs between the molecules and proteins within a cell and between cells. Understanding the molecular pathways that contribute to or are affected by a disease plays a critical role in helping scientists select the best therapeutic targets.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/pathway", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":10, "parent":5, "color":"#d32f2f", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1092, "submap_id":2, "object_id":11, "function":"List", "sub_function":"Database Clinical", "relationship":"Database Clinical", "submap_node_parent_id":1, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Data Repository", "label_name":"Data Repository", "group_name":"Basic Science Research", "reference_synonym":"digital data repository", "identifier_CUI":"C3830485", "NCI_thesaurus_code":null, "semantic_type":"Manufactured Object; T073", "sematic_type_code":"T073", "Level_II_Source":"NCI", "Level_II_Description":"A digital library in which collections, or archives, of content items are stored in digital format. File based or database. Child entities = Archive A digital library in which collections, or archives, of content items are stored in digital format.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"CARELEX", "Alt_Identifier_CUI":"CARELEX", "Level_II_Alt_Description":"A digital library in which collections, or archives, of content items are stored in digital format.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Data repositories are information warehouses where large amounts of data from multiple sources are stored. Examples of the types of data that can be stored in data repositories include scientific publications, research data, or clinical information.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/repositories", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":11, "parent":1, "color":"#d32f2f", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1093, "submap_id":2, "object_id":12, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":11, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Genotypes", "label_name":"Genotypes", "group_name":"Basic Science Research", "reference_synonym":"Genotype", "identifier_CUI":"C0017431", "NCI_thesaurus_code":null, "semantic_type":"Organism Attribute", "sematic_type_code":"T032", "Level_II_Source":"NCI", "Level_II_Description":"At its broadest level, genotype includes the entire genetic constitution of an individual. It is often applied more narrowly to the set of alleles present at one or more specific loci.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"At its broadest level, genotype includes the entire genetic constitution of an individual. It is often applied more narrowly to the set of alleles present at one or more specific loci.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"A genotype is an individual's genetic makeup, which is stored in their DNA. DNA is packaged into 23 chromosomes, and every person has two copies of each chromosome, with one copy inherited from each parent (46 total chromosomes). Each chromosome contains certain genes that code for specific molecular processes and traits, and different versions of the same gene are called alleles. Combinations of these alleles create genotypes, and genotype determines phenotype. Understanding genotypes is important in drug development because a person may have the genetic variants for a specific severe disease, but they may not show phenotypic evidence of said disease. Because of this, they would not be getting the treatment that they require, leading to potentially life threatening outcomes. An example of this dilemma would be a woman with the BRCA1/2 gene. There would be no outright, phenotypic signs of the gene's presence in the patient's genome until cancer is actually diagnosed, at which point it may be too late to save the woman. ", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/genotypes", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":12, "parent":11, "color":"#d32f2f", "nodeLocContent":[ {"ObjectId":12, "name":"import 2", "display_name":"ARUP Laboratories Inc.", "uri":"https://www.aruplab.com/trials", "uri_display_name":"ARUP Trial website", "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"31 center drive", "city":"Bethesda", "state":"MD", "zip":"20894", "lat":39.0035707, "lng":-77.1013313},{"ObjectId":12, "name":"import 1", "display_name":"ARUP Laboratories Inc.", "uri":"https://www.aruplab.com/trials", "uri_display_name":"ARUP Trial website", "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"500 Chipeta Way", "city":"Salt Lake City", "state":"UT", "zip":"84108\r", "lat":40.7570702, "lng":-111.8252594},{"ObjectId":12, "name":"import 2", "display_name":"ARUP Laboratories Inc.", "uri":"https://www.aruplab.com/trials", "uri_display_name":"ARUP Trial website", "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"31 center drive", "city":"Bethesda", "state":"MD", "zip":"20894", "lat":39.0035707, "lng":-77.1013313},{"ObjectId":12, "name":"import 1", "display_name":"ARUP Laboratories Inc.", "uri":"https://www.aruplab.com/trials", "uri_display_name":"ARUP Trial website", "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"500 Chipeta Way", "city":"Salt Lake City", "state":"UT", "zip":"84108\r", "lat":40.7570702, "lng":-111.8252594},{"ObjectId":12, "name":"ARUP Laboratories", "display_name":"ARUP Laboratories Inc.", "uri":"https://www.aruplab.com/trials", "uri_display_name":"ARUP Trial website", "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"31 center drive", "city":"Bethesda", "state":"MD", "zip":"20894", "lat":39.0035707, "lng":-77.1013313},{"ObjectId":12, "name":"ARUP Laboratories", "display_name":"ARUP Laboratories Inc.", "uri":"https://www.aruplab.com/trials", "uri_display_name":"ARUP Trial website", "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"31 center drive", "city":"Bethesda", "state":"MD", "zip":"20894", "lat":39.0035707, "lng":-77.1013313},{"ObjectId":12, "name":"Geno 6th", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"Test", "poc_last_name":"tewt", "poc_email":"test@ted.com", "street_address":"987 Massachusetts Avenue", "city":"Cambridge", "state":"MA", "zip":"02138", "lat":42.369356, "lng":-71.1108143},{"ObjectId":12, "name":"geno 5h", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"geno5th", "poc_last_name":"last", "poc_email":"lasat@test.com", "street_address":"4500 East West Highway", "city":"Bethesda", "state":"MD", "zip":"20814", "lat":38.9844788, "lng":-77.0912074},{"ObjectId":12, "name":"geno 4th", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"geno4th", "poc_last_name":"last", "poc_email":"lasat@test.com", "street_address":"123 Landmark Alley", "city":"Statesville", "state":"NC", "zip":"28677", "lat":35.7853845, "lng":-80.889766},{"ObjectId":12, "name":"geno 3rd", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"geno3rd", "poc_last_name":"last", "poc_email":"lasat@test.com", "street_address":"123 Chestnut Street", "city":"Philadelphia", "state":"PA", "zip":"19106", "lat":39.948524, "lng":-75.143615},{"ObjectId":12, "name":"geno 2nd", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"geno2nd", "poc_last_name":"last", "poc_email":"test@test.com", "street_address":"10650 Pyramid Place", "city":"Manassas", "state":"VA", "zip":"20110", "lat":38.7562359, "lng":-77.5153234},{"ObjectId":12, "name":"Genotypes", "display_name":"Genotypes", "uri":"https://ncats.nih.gov", "uri_display_name":"ncats website", "description":"Genotypes description", "poc_first_name":"Mike Jr", "poc_last_name":"Test", "poc_email":"mike@tst.coim", "street_address":"9800 Medical Center Drive", "city":"Rockville", "state":"MD", "zip":"20850", "lat":39.0958297, "lng":-77.197237} ], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1094, "submap_id":2, "object_id":13, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":11, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Phenotypes", "label_name":"Phenotypes", "group_name":"Clinical Research", "reference_synonym":"Phenotype", "identifier_CUI":"C0031437", "NCI_thesaurus_code":null, "semantic_type":"Organism Attribute", "sematic_type_code":"T032", "Level_II_Source":"NCI", "Level_II_Description":"The assemblage of traits or outward appearance of an individual. It is the product of interactions between genes and between genes and the environment.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"The observable characteristics in an individual resulting from the expression of genes; the clinical presentation of an individual with a particular genotype.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"An individualâ€™s phenotype refers to their observable traits, such as height or eye color. This is the physical expression of an individualâ€™s genes, or genotype. DNA is packaged into 23 chromosomes, and every person has two copies of each chromosome, with one copy inherited from each parent (46 total chromosomes). Each chromosome contains certain genes that code for specific molecular processes and traits, and different versions of the same gene are called alleles. Combinations of these alleles create genotypes, which translate to phenotypes. In addition to genetic factors, a personâ€™s phenotype is also influenced by environmental factors. Phenotypes have played a role in drug development for a long time. Researchers develop drugs and then monitor the observable, or phenotypical, changes as a response to the drug. If the drug produces positive phenotypical results, that means the drug is beneficial.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/phenotypes", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":13, "parent":11, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1095, "submap_id":2, "object_id":14, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":1, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Biorepositories", "label_name":"Biorepository", "group_name":"Basic Science Research", "reference_synonym":"Biorepository", "identifier_CUI":"C1711176", "NCI_thesaurus_code":null, "semantic_type":"Manufactured Object; T073", "sematic_type_code":"T073", "Level_II_Source":"NCI", "Level_II_Description":"A storage facility of biospecimens that includes tissue samples, fluids, and molecular derivatives such as DNA, RNA, and proteins. The biorepository has stringent guidelines regarding the standardized collection, handling, storage, and documentation of biological specimens.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"A facility that collects, catalogs, and stores samples of biological material, such as urine, blood, tissue, cells, DNA, RNA, and protein, from humans, animals, or plants for laboratory research. If the samples are from people, medical information may also be stored along with a written consent to use the samples in laboratory studies.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Biorepositories are places for storing biological samples (also called biospecimens) such as blood samples, tumor samples, or other tissue. The type of biological samples stored in biorepositories will vary depending upon the type of disease and nature of research.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/biorepositories", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":14, "parent":1, "color":"#d32f2f", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1096, "submap_id":2, "object_id":15, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Biomarker Development", "label_name":"Biomarker Identification", "group_name":"Biomarker Development", "reference_synonym":"Mechanism of Action", "identifier_CUI":"C1524059", "NCI_thesaurus_code":null, "semantic_type":"Functional Concept; T169", "sematic_type_code":"T169", "Level_II_Source":"NCI", "Level_II_Description":"The mechanism by which a pharmacologically active substance produces an effect on a living organism or in a biochemical system.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCATS", "Alt_Identifier_CUI":"NCATS", "Level_II_Alt_Description":"The study of a biological target - typically a protein or genetic material - that is hypothesized to play a key role in the pathology of a disease and how the function of that target can be modulated by a chemical compound to produce a therapeutic physiological effect.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":15, "parent":116, "color":"#c64e00", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1097, "submap_id":2, "object_id":16, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":19, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Pharmacology and Target Engagement", "label_name":"Pharmacology / Target Engagement", "group_name":"Biomarker Development", "reference_synonym":null, "identifier_CUI":"C1258062", "NCI_thesaurus_code":null, "semantic_type":"Molecular Function; T044", "sematic_type_code":"T044", "Level_II_Source":"NCI", "Level_II_Description":"Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY.", "Level_II_Link":null, "Level_II_Synonym":"Pharmacological Mechanisms of Action", "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"Nature.com search", "Alt_Description2":"A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal biological or pathological processes, or a response to a therapeutic intervention. Examples include patterns of gene expression, levels of a particular protein in body fluids, or changes in electrical activity in the brain.", "Alt_URL2":"https://www.nature.com/subjects/biomarkers?WT.ac=search_subjects_biomarkers", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"BEST (Biomarkers, Endpoints, and other Tools) Resource", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://www.ncbi.nlm.nih.gov/books/NBK326791/", "bottleneck":null, "key":16, "parent":19, "color":"#c64e00", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1098, "submap_id":2, "object_id":19, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":15, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Biomarker Development Program", "label_name":"Biomarker Development Program", "group_name":"Biomarker Development", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":null, "sematic_type_code":null, "Level_II_Source":"NCATS", "Level_II_Description":"Multidisciplinary programs that develop biomarkers as tools for multiple purposes including drug development, diagnostic tools, treatment endpoints.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":19, "parent":15, "color":"#c64e00", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1099, "submap_id":2, "object_id":21, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":19, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Prognostic & Predictive Biomarker", "label_name":"Prognostic & Predictive Biomarker", "group_name":"Biomarker Development", "reference_synonym":"Predictive", "identifier_CUI":"C1880302", "NCI_thesaurus_code":null, "semantic_type":"Diagnostic Procedure; T060", "sematic_type_code":"T060", "Level_II_Source":"Wikipedia", "Level_II_Description":"Predictive biomarkers are used to help optimize ideal treatments and indicates the likelihood of benefiting from a specific therapy. Biomarkers for precision oncology are typically utilized in the molecular diagnostics ofÂ chronic myeloid leukemia,Â colon,Â breast, andÂ lungÂ cancer, and inÂ melanoma.", "Level_II_Link":"https://en.wikipedia.org/wiki/Biomarker", "Level_II_Synonym":null, "Level_II_Alt_Source":"BEST Glossary", "Alt_Identifier_CUI":"BEST Glossary", "Level_II_Alt_Description":"A biomarker used to identify individuals who are more likely than similar individuals without the biomarker to experience a favorable or unfavorable effect from exposure to a medical product or an environmental agent.", "Level_II_alt_Link":"https://www.ncbi.nlm.nih.gov/books/NBK338448/def-item/predictive-biomarker/", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"BEST (Biomarkers, Endpoints, and other Tools) Resource", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://www.ncbi.nlm.nih.gov/books/NBK326791/", "bottleneck":null, "key":21, "parent":19, "color":"#c64e00", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1100, "submap_id":2, "object_id":22, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":19, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Response Biomarker", "label_name":"Response Biomarker", "group_name":"Biomarker Development", "reference_synonym":"Prognostic Biomarker", "identifier_CUI":"C1955888", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"Wikipedia", "Level_II_Description":"Prognostic biomarkers indicate the likelihood of patient outcome regardless of a specific treatment", "Level_II_Link":"https://en.wikipedia.org/wiki/Biomarker", "Level_II_Synonym":"Drug Response Biomarkers", "Level_II_Alt_Source":"BEST Glossary", "Alt_Identifier_CUI":"BEST Glossary", "Level_II_Alt_Description":"A biomarker used to show that a biological response has occurred in an individual who has been exposed to a medical product or an environmental agent.", "Level_II_alt_Link":"https://www.ncbi.nlm.nih.gov/books/NBK338448/def-item/pharmacodynamic-response-biomarker/", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"BEST (Biomarkers, Endpoints, and other Tools) Resource", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://www.ncbi.nlm.nih.gov/books/NBK326791/", "bottleneck":null, "key":22, "parent":19, "color":"#c64e00", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1101, "submap_id":2, "object_id":23, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":15, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Qualification", "label_name":"Qualification", "group_name":"Biomarker Development", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"BEST Glossary", "Level_II_Description":"A conclusion, based on a formal regulatory process, that within the stated context of use, a medical product development tool can be relied upon to have a specific interpretation and application in medical product development and regulatory review.", "Level_II_Link":"https://www.ncbi.nlm.nih.gov/books/NBK338448/#IX-Q", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"BEST (Biomarkers, Endpoints, and other Tools) Resource", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://www.ncbi.nlm.nih.gov/books/NBK326791/", "bottleneck":null, "key":23, "parent":15, "color":"#c64e00", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1102, "submap_id":2, "object_id":24, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":23, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Companion Diagnostic", "label_name":"Companion Diagnostic", "group_name":"Biomarker Development", "reference_synonym":"Positive Predictive Value of Diagnostic Test", "identifier_CUI":"C1514243", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"The probability that an individual is affected with the condition when a positive test result is observed. Predictive values should only be calculated from cohort studies or studies that legitimately reflect the number of people in the population who have the condition of interest at that time since predictive values are inherently dependent upon the prevalence. PPVDT can be determined by calculating: number of true positive results divided by the sum of true positive results plus number of false positive results.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA: Medical Devices", "Alt_Identifier_CUI":"FDA: Medical Devices", "Level_II_Alt_Description":"A companion diagnostic is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The test helps a health care professional determine whether a particular therapeutic productâ€™s benefits to patients will outweigh any potential serious side effects or risks. Companion diagnostics can: identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.", "Level_II_alt_Link":"https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297.htm", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":24, "parent":23, "color":"#c64e00", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1103, "submap_id":2, "object_id":25, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":23, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Surrogate Endpoint", "label_name":"Surrogate Endpoint", "group_name":"Biomarker Development", "reference_synonym":"Surrogate Endpoints", "identifier_CUI":"C0162488", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"NCI", "Level_II_Description":"A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. The term surrogate endpoint applies primarily to endpoints in therapeutic intervention trials; however, it may sometimes apply in natural history or epidemiologic studies. The use of biomarkers as surrogate endpoints in a clinical trial requires the specification of the clinical endpoints that are being substituted, class of therapeutic intervention being applied, and characteristics of population and disease state in which the substitution is being made.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"BEST Glossary", "Alt_Identifier_CUI":"BEST Glossary", "Level_II_Alt_Description":"An endpoint that is used in clinical trials as a substitute for a direct measure of how a patient feels, functions, or survives. A surrogate endpoint does not measure the clinical benefit of primary interest in and of itself, but rather is expected to predict that clinical benefit or harm based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence.", "Level_II_alt_Link":"https://www.ncbi.nlm.nih.gov/books/NBK326791/", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":25, "parent":23, "color":"#c64e00", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1104, "submap_id":2, "object_id":26, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Lead Identification Map", "label_name":"Lead Identification Map", "group_name":"Lead Identification", "reference_synonym":"Chemical OR drug identification procedure, Hit to Lead, Lead Generation", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"Wikipedia", "Level_II_Description":"Hit to leadÂ (H2L) also known asÂ lead generationÂ is a stage in earlyÂ drug discoveryÂ whereÂ small moleculeÂ hits from aÂ high throughput screenÂ (HTS) are evaluated and undergo limited optimization to identify promisingÂ lead compounds. [1][2]Â These lead compounds undergo more extensive optimization in a subsequent step of drug discovery calledÂ lead optimizationÂ (LO). [3][4]Â ", "Level_II_Link":"https://en.wikipedia.org/wiki/Hit_to_lead", "Level_II_Synonym":null, "Level_II_Alt_Source":"NCATS", "Alt_Identifier_CUI":"NCATS", "Level_II_Alt_Description":"This is the process whereby \"hits\" (i.e. chemical compounds that produce the desired effect in an initial high-throughput screening assay) are further tested in alternate assays to confirm their ability to modulate the pharmacological or therapeutic target in the desired manner. \"Leads\" can undergo additional optimization through medicinal chemistry studies seeking to uncover the relationship between the compound's chemical structure and its function as a potential therapeutic drug.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"NCATS Chemical Genomics Center (NCGC)", "NCATS_Program_1_Label":"Chemical Genomics Center", "NCATS_Program_Link_1":"https://ncats.nih.gov/ncgc", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"Assay Guidance Manual", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://ncats.nih.gov/expertise/preclinical/agm", "bottleneck":null, "key":26, "parent":116, "color":"#401900", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1105, "submap_id":2, "object_id":27, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":26, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Assay Development Small Molecule", "label_name":"Assay Development Small Molecule", "group_name":"Lead Identification", "reference_synonym":"Assay Development", "identifier_CUI":"C0872102", "NCI_thesaurus_code":null, "semantic_type":"Diagnostic Procedure; T060", "sematic_type_code":"T060", "Level_II_Source":"Wikipedia", "Level_II_Description":"AnÂ assayÂ is an investigative (analytic) procedure inÂ laboratory medicine,Â pharmacology,Â environmental biologyÂ andÂ molecular biologyÂ for qualitatively assessing or quantitatively measuring the presence, amount, or functional activity of a target entity (the analyte). The analyte can be aÂ drug, aÂ biochemical substance, or aÂ cellÂ in anÂ organismÂ or organicÂ sample. [1][2]Â The measured entity is generally called theÂ analyte, theÂ measurandÂ or theÂ targetÂ of the assay. The assay usually aims to measure anÂ intensive propertyÂ of the analyte and express it in the relevant measurement unit (e.g.Â molarity,Â density, functional activity in enzyme international units, degree of some effect in comparison to a standard, etc.).", "Level_II_Link":"https://en.wikipedia.org/wiki/Assay", "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"An assay is an analytical test that measures the activity of a small molecule or biologic on a target of interest. For example, some assays measure the effect that compounds have on the activity of an enzyme, while others measure the effect that compounds have on protein expression. Researchers develop assays to identify compounds that have a desired effect on a therapeutic target, and thus have potential as therapeutics. Different assays must be developed for different targets of interest, as different targets have different characteristics.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/development", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Assay Development and Screening Technology (ADST) Laboratory", "NCATS_Program_1_Label":"Assay Development", "NCATS_Program_Link_1":"https://ncats.nih.gov/adst", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"Assay Guidance Manual", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://ncats.nih.gov/expertise/preclinical/agm", "bottleneck":null, "key":27, "parent":26, "color":"#401900", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1106, "submap_id":2, "object_id":28, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":27, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"HTS Assays SM", "label_name":"HTS Assays SM", "group_name":"Lead Identification", "reference_synonym":"high-throughput screening assays", "identifier_CUI":"C2718002", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"MSH", "Level_II_Description":"Rapid methods of measuring the effects of an agent in a biological or chemical assay. The assay usually involves some form of automation or a way to conduct multiple assays at the same time using sample arrays.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"MSH", "Alt_Identifier_CUI":"MSH", "Level_II_Alt_Description":"Rapid methods of measuring the effects of an agent in a biological or chemical assay. The assay usually involves some form of automation or a way to conduct multiple assays at the same time using sample arrays.", "Level_II_alt_Link":null, "Alt_Synonym2":"high-throughput screening", "Alt_Source2":"Nature.com search", "Alt_Description2":"High-throughput screening methods provide efficient measurement of the effects of agents or conditions in biological or chemical assays. These methods often require robotics, imaging and computation to increase the scale and speed of assays.", "Alt_URL2":"https://www.nature.com/subjects/high-throughput-screening?WT.ac=search_subjects_high_throughput_screening", "NCATS_Program_1":"NCATS Chemical Genomics Center (NCGC)", "NCATS_Program_1_Label":"Chemical Genomics Center", "NCATS_Program_Link_1":"https://ncats.nih.gov/ncgc", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"Assay Guidance Manual", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://ncats.nih.gov/expertise/preclinical/agm", "bottleneck":null, "key":28, "parent":27, "color":"#401900", "nodeLocContent":[ {"ObjectId":28, "name":"hts local content123", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"asdfas", "poc_last_name":"asdf", "poc_email":"asdf@asdf.com", "street_address":"2341 2nd Avenue", "city":"New York", "state":"NY", "zip":"10035", "lat":40.799781, "lng":-73.936107} ], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1107, "submap_id":2, "object_id":29, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":31, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Library of Small Molecules and Chemical  Compound ", "label_name":"Libraries Small Molecules and Chemical  Compound ", "group_name":"Lead Identification", "reference_synonym":"Small Molecule Libraries", "identifier_CUI":"C0598139", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NETS", "Level_II_Description":"Large collections of small molecules (molecular weight about 600 or less), of similar or diverse nature which are used for high-throughput screening analysis of the gene function, protein interaction, cellular processing, biochemical pathways, or other chemical interactions.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Compound libraries are stores of chemical compounds or small molecules. They contain detailed information on the physical structure and known physiological interactions of each chemical compound. This information can help researchers identify the compounds that are most likely to produce the desired effect on a therapeutic target.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/libraries", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"NCATS Chemical Genomics Center (NCGC)", "NCATS_Program_1_Label":"Chemical Genomics Center", "NCATS_Program_Link_1":"https://ncats.nih.gov/ncgc", "NCATS_Program_2":"Compound Management", "NCATS_Program_2_Label":"Compound Management", "NCATS_Program_Link_2":"https://ncats.nih.gov/preclinical/core/compound", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":29, "parent":31, "color":"#401900", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1108, "submap_id":2, "object_id":30, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":31, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Cheminformatics", "label_name":"Chemical Informatics", "group_name":"Lead Identification", "reference_synonym":"Cheminformatics", "identifier_CUI":"C1328808", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"CSP", "Level_II_Description":"Informatics technologies that integrate chemical data with analytic and molecular design tools; cheminformatics applications provide access to compound related information, including chemical structure, properties, structure activity relationships, etc.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"CSP", "Alt_Identifier_CUI":"CSP", "Level_II_Alt_Description":"Informatics technologies that integrate chemical data with analytic and molecular design tools; cheminformatics applications provide access to compound related information, including chemical structure, properties, structure activity relationships, etc.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Informatics", "NCATS_Program_1_Label":"Informatics", "NCATS_Program_Link_1":"https://ncats.nih.gov/preclinical/core/informatics", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":30, "parent":31, "color":"#401900", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1109, "submap_id":2, "object_id":31, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":26, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"High Throughput Screening  System (HTS)", "label_name":"HTS System", "group_name":"Lead Identification", "reference_synonym":"high-throughput screening", "identifier_CUI":"C0872187", "NCI_thesaurus_code":null, "semantic_type":"Diagnostic Procedure; T060", "sematic_type_code":"T060", "Level_II_Source":"NCI", "Level_II_Description":"Use of robots and other automated techniques to screen large numbers of samples.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"Nature.com search", "Alt_Identifier_CUI":"Nature.com search", "Level_II_Alt_Description":"High-throughput screening methods provide efficient measurement of the effects of agents or conditions in biological or chemical assays. These methods often require robotics, imaging and computation to increase the scale and speed of assays.", "Level_II_alt_Link":"https://www.nature.com/subjects/high-throughput-screening?WT.ac=search_subjects_high_throughput_screening", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"NCATS Chemical Genomics Center (NCGC)", "NCATS_Program_1_Label":"Chemical Genomics Center", "NCATS_Program_Link_1":"https://ncats.nih.gov/ncgc", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"Assay Guidance Manual", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://ncats.nih.gov/expertise/preclinical/agm", "bottleneck":null, "key":31, "parent":26, "color":"#401900", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1110, "submap_id":2, "object_id":32, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":31, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Identified Misses SM", "label_name":"Identified Misses SM", "group_name":"Lead Identification", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Misses are compounds that do not produce the desired effect in high-throughput screening (HTS) assays. This means that the compound failed to produce the desired effect only in one specific assay. Compounds that do not work in an assay for one disease might be effective in an assay for a different disease.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/misses", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":32, "parent":31, "color":"#401900", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1111, "submap_id":2, "object_id":33, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":31, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Hits Identified SM", "label_name":"Hits Identified SM", "group_name":"Lead Identification", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"A â€˜hitâ€™ is a compound that produces the desired effect in an HTS system and therefore qualifies for additional investigation into its potential therapeutic effects.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/hits ", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":33, "parent":31, "color":"#401900", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1112, "submap_id":2, "object_id":34, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":31, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Unapproved Compounds (NCE/NME)", "label_name":"Candidate Compounds (NCE/NME)", "group_name":"Lead Identification", "reference_synonym":"New Chemical/Molecular Entities", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Governmental or Regulatory Activity; T064", "sematic_type_code":"T064", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Unapproved compounds are drugs or small molecules that have not received FDA approval for use in humans. Preclinical and clinical studies are needed to determine whether an unapproved compound is safe to test in humans. Unapproved compounds may be classified as new chemical entities (NCE) or new molecular entities (NME). Both contain novel active moieties (the part of the compound that gives the specific physiological or pharmacological function).", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/unapproved", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":34, "parent":31, "color":"#401900", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1113, "submap_id":2, "object_id":35, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Lead Optimization", "label_name":"Lead Optimization", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"NCATS", "Level_II_Description":"A lead optimization candidate is a chemical compound that has demonstrated sufficient efficacy in multiple assays without overly toxic side effects and has sufficient potential for development into a new drug that it justifies further optimization and development.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"NCATS Chemical Genomics Center (NCGC)", "NCATS_Program_1_Label":"Chemical Genomics Center", "NCATS_Program_Link_1":"https://ncats.nih.gov/ncgc", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":35, "parent":116, "color":"#517482", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1114, "submap_id":2, "object_id":36, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":35, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Lead Compounds", "label_name":"Lead Compounds", "group_name":"Lead Optimization", "reference_synonym":"Development Candidates", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Chemical Viewed Structurally; T104", "sematic_type_code":"T104", "Level_II_Source":"Wikipedia", "Level_II_Description":"A lead compound in drug discovery is a chemical compound that has pharmacological or biological activity likely to be therapeutically useful, but may nevertheless have suboptimal structure that requires modification to fit better to the target; lead drugs offer the prospect of being followed by back-up compounds. Its chemical structure serves as a starting point for chemical modifications in order to improve potency, selectivity, or pharmacokinetic parameters. Furthermore, newly invented pharmacologically active moieties may have poor drug likeness and may require chemical modification to become drug-like enough to be tested biologically or clinically. [1]", "Level_II_Link":"https://en.wikipedia.org/wiki/Lead_compound", "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"A lead compound is a molecule or collection of molecules that demonstrates the desired response against a specific biological target and therefore has potential therapeutic use. Often, lead compounds are identified from compound libraries using a HTS system. Additional research and medicinal chemistry are needed to turn lead compounds into potential therapies.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/lead", "Alt_Synonym2":null, "Alt_Source2":"GSK Glossary", "Alt_Description2":"The best exemplar of a chemical series that has a pharmacological or biological activity and has suitable chemical properties to act as a starting point for further chemical optimization. Typically, a lead shows appropriate activity at the target, demonstrates activity in a relevant cell-based assay and has a tractable structure-activity relationship (SAR) with potential to achieve the required activity, selectivity, physicochemical characteristics, patentability and bioavailability of a candidate quality molecule.", "Alt_URL2":"http://www.dpac.gsk.com/glossary.html", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":36, "parent":35, "color":"#517482", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1115, "submap_id":2, "object_id":37, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"In silico Modelling", "label_name":"In silico Modelling", "group_name":"Lead Optimization", "reference_synonym":"Computer Simulation", "identifier_CUI":"C0009609", "NCI_thesaurus_code":null, "semantic_type":"Machine Activity; T066", "sematic_type_code":"T066", "Level_II_Source":"NCI", "Level_II_Description":"A technique which attempts to provide an abstract model of a particular system. It utilizes a mathematical model, which attempts to predict the behavior of the system from a set of parameters and initial conditions.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCATS", "Alt_Identifier_CUI":"NCATS", "Level_II_Alt_Description":"In silico modeling refers to the use of computational models of biological and chemical processes, including interactions between a chemical compound and its pharmacological or therapeutic target, to aid in the further development of a drug compound. These models aid the exploration and visualization of molecular structures and properties and the design and optimization of biologically active compounds with desired structure and properties.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":37, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1116, "submap_id":2, "object_id":38, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Lead Candidate Optimization", "label_name":"Lead Candidate Optimization (SM)", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Nature.com", "Level_II_Description":"Lead optimization is the process by which a drug candidate is designed after an initial lead compound is identified. The process involves iterative rounds of synthesis and characterization of a potential drug to build up a picture of how chemical structure and activity are related in terms of interactions with its targets and its metabolism.", "Level_II_Link":"https://www.nature.com/subjects/lead-optimization", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"GSK Glossary", "Alt_Description2":"Process in which the drug-like properties of an initial lead or lead series are improved. Typically, biological activity will be enhanced, in vivo efficacy will be demonstrated and compounds with a physicochemical, pharmacological and toxicological profile consistent with progression to the clinic will be identified.", "Alt_URL2":"http://www.dpac.gsk.com/glossary.html", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":38, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1117, "submap_id":2, "object_id":39, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Medicinal Chemistry", "label_name":"Medicinal Chemistry", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"C0008003", "NCI_thesaurus_code":null, "semantic_type":"Biomedical Occupation or Discipline", "sematic_type_code":"T091", "Level_II_Source":"NCI", "Level_II_Description":"A chemistry-based discipline, also involving aspects of biological, medical and pharmaceutical sciences. It is concerned with the invention, discovery, design, identification and preparation of biologically active compounds, the study of their metabolism, the interpretation of their mode of action at the molecular level and the construction of structure-activity relationships.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Medicinal chemistry is the design and synthesis of chemical compounds intended to be used as medicine in humans. Using medicinal chemistry, compounds that are initially identified as having potential therapeutic effects can be optimized to reduce unwanted side effects and improve their interaction with the therapeutic target.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/medicinal", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Chemistry Technology", "NCATS_Program_1_Label":"Chemistry Technology", "NCATS_Program_Link_1":"https://ncats.nih.gov/chemtech", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":39, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1118, "submap_id":2, "object_id":40, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"In vitro Functional and Safety Screening", "label_name":"In vitro Screening", "group_name":"Lead Optimization", "reference_synonym":"In vitro drug evaluation", "identifier_CUI":"C0013206", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"MSH", "Level_II_Description":"Preclinical testing of drugs in vitro for their biological and toxic effects and potential clinical applications.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":40, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1119, "submap_id":2, "object_id":41, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Process Chemistry", "label_name":"Process Chemistry", "group_name":"Lead Optimization", "reference_synonym":"Organic Chemistry Processes", "identifier_CUI":"C2350460", "NCI_thesaurus_code":null, "semantic_type":"Natural Phenomenon or Process", "sematic_type_code":"T070", "Level_II_Source":"CUI wo Def", "Level_II_Description":"Pending Priority", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"Wikipedia", "Alt_Identifier_CUI":"Wikipedia", "Level_II_Alt_Description":"Process chemistry is the arm of pharmaceutical chemistry concerned with the development and optimization of a synthetic scheme and pilot plant procedure to manufacture compounds for the drug development phase. Process chemistry is distinguished from medicinal chemistry, which is the arm of pharmaceutical chemistry tasked with designing and synthesizing molecules on small scale in the early drug discovery phase.", "Level_II_alt_Link":"https://en.wikipedia.org/wiki/Process_chemistry", "Alt_Synonym2":null, "Alt_Source2":"American Chemical Society blog", "Alt_Description2":"Process chemistry is often described as scaling up reactions, taking them from the small quantities created in the research lab to the larger quantities that are needed for further testing and then to even larger quantities required for commercial production. The goal of a process chemist is to develop synthetic routes that are safe, cost-effective, environmentally friendly, and efficient (in both time and atoms). ", "Alt_URL2":"https://www.acs.org/content/acs/en/careers/college-to-career/chemistry-careers/process-chemistry.html", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":41, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1120, "submap_id":2, "object_id":42, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Non-GMP Supply and Early CMC", "label_name":"Non-GMP Supply / Early CMC", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":null, "sematic_type_code":null, "Level_II_Source":null, "Level_II_Description":"Pending Priority", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":42, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1121, "submap_id":2, "object_id":43, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":35, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Candidate Compounds Small Molecule", "label_name":"Candidate Compounds", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"NCATS", "Level_II_Description":"Candidate compounds are former lead compounds that have sufficiently advanced through preclinical studies including medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics. Candidate compounds must go through additional testing in whole organisms to measure compound efficacy and toxicology before it can be submitted to the FDA as part of an Investigational New Drug (IND) application to begin first-in-human clinical trials.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":43, "parent":35, "color":"#517482", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1122, "submap_id":2, "object_id":44, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":43, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Non-GLP Studies", "label_name":"Non-GLP Studies", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Good Laboratory Practices (GLP) is a certification issued by regulatory bodies to ensure that the data submitted to them has been obtained using the proper procedures. GLP certification also ensures that the protocols used were thoroughly documented such that any scientist could follow the protocol and replicate the results. Non-GLP practices are not â€˜badâ€™ or â€˜inferiorâ€™ â€“ rather, they lack the extensive documentation needed to qualify for GLP certification. For the early phases of pre-clinical research, it is unnecessary to adhere to these requirements. Carrying out initial non-GLP studies in the areas of toxicology and pharmacology will preserve both time and funding.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/non_GLP", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":44, "parent":43, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1123, "submap_id":2, "object_id":45, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":43, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Investigative In Vitro/In Vivo Safety & Toxicology", "label_name":"Investigative Safety & Toxicology", "group_name":"Lead Optimization", "reference_synonym":"Toxicology studies", "identifier_CUI":"C0808279", "NCI_thesaurus_code":null, "semantic_type":"Biomedical Occupation or Discipline", "sematic_type_code":"T091", "Level_II_Source":"CUI wo Def", "Level_II_Description":"Pending Priority", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCATS", "Alt_Identifier_CUI":"NCATS", "Level_II_Alt_Description":"The scientific analysis of the effects of an investigational drug compound on cultured cells (in vitro) or in living animals (in vivo) to identify potentially hazardous or toxic effects of the compound prior to testing in humans. The purpose is to test whether certain compounds have the potential to disrupt processes in the human body that may lead to negative health effects.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":45, "parent":43, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1124, "submap_id":2, "object_id":46, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":43, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"In Vitro / In Vivo Pharmacology", "label_name":"In vitro / In Vivo Pharmacology", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Pharmacology is the study of the biological effects of drugs. In vitro pharmacology studies the biological effects of a drug in an isolated environment, such as cell lines or tissues. This setup conveniently eliminates whole organism physiological influences allowing for a detailed analysis a compound's impact. In vivo pharmacology is the study of the biological effects of a drug in a complex living organism and is used to observe the complex physiological effects of a drug.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/in_vitro", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":46, "parent":43, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1125, "submap_id":2, "object_id":47, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":43, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Safety", "label_name":"Safety", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"In preclinical drug development, safety refers to a therapeutic index or numerical value that represents a drugâ€™s harmful effects compared to its therapeutic effects. This value is determined through acute toxicology studies. Larger therapeutic indexes are indicative of safer substances", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/safety", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":47, "parent":43, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1126, "submap_id":2, "object_id":48, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":43, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Effectiveness and POC", "label_name":"Effectiveness and POC", "group_name":"Lead Optimization", "reference_synonym":"Efficacy & Proof of Concept", "identifier_CUI":"C4505280", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NETS", "Level_II_Description":"An empirical investigation which pertains to the development of prototypes or models that demonstrate the feasibility of novel concepts, ideas, principles, schema or their practical application.", "Level_II_Link":null, "Level_II_Synonym":"Proof of Concept Study", "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Efficacy and proof of concept demonstrate that a compound is capable of having the desired therapeutic effects.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/efficacy", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":48, "parent":43, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1127, "submap_id":2, "object_id":49, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":43, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Predicted Therapeutic Dose/Exposure", "label_name":"Predicted Therapeutic Dose / Exposure", "group_name":"Lead Optimization", "reference_synonym":"Dose", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Dose refers to the quantity or concentration of drug that is administered. During pre-clinical research, data is collected on the safety and efficacy of a drug at different doses. This data is used to select the dose or doses that will maximize therapeutic benefits and keep harmful side effects at a minimum.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/dose", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":49, "parent":43, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1128, "submap_id":2, "object_id":50, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Early cGMP Manufacturing", "label_name":"Early cGMP Manufacture", "group_name":"Lead Optimization", "reference_synonym":"cGMP Manufacturing", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Machine Activity; T066", "sematic_type_code":"T066", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Current Good Manufacturing Practices (cGMP) are part of a quality assurance system monitoring the manufacture and testing of drugs. Before a compound can be tested in humans, regulatory bodies require compound sponsors to demonstrate that a compound has been manufactured in accordance with these quality standards.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/cGMP", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":50, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1129, "submap_id":2, "object_id":51, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"GLP Pharmacokinetics", "label_name":"GLP Pharmaco- kinetics", "group_name":"Lead Optimization", "reference_synonym":"Drug Kinetics", "identifier_CUI":"C0031327", "NCI_thesaurus_code":null, "semantic_type":"Classification; T185", "sematic_type_code":"T185", "Level_II_Source":"NCI", "Level_II_Description":"Study of the processes of bodily absorption, distribution, metabolism, and excretion (ADME) of medicinal products.", "Level_II_Link":null, "Level_II_Synonym":"Good Laboratory Practice Type", "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"The activity of drugs in the body over a period of time, including the processes by which drugs are absorbed, distributed in the body, localized in the tissues, and excreted.", "Level_II_alt_Link":null, "Alt_Synonym2":"PK (ADME)", "Alt_Source2":"NETS Map", "Alt_Description2":"Pharmacokinetics (PK) is the study of how the body metabolizes a drug and how this drug is distributed throughout the body. PK (ADME) refers to pharmacokinetic (PK) studies that quantitatively measure the absorption, distribution, metabolism and elimination (ADME) of a compound in a living organism.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/PK", "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":51, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1130, "submap_id":2, "object_id":52, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"GLP Pharmacology", "label_name":"GLP Pharmacology", "group_name":"Lead Optimization", "reference_synonym":"Pharmacology", "identifier_CUI":"C0031330", "NCI_thesaurus_code":null, "semantic_type":"Biomedical Occupation or Discipline", "sematic_type_code":"T091", "Level_II_Source":"NCIÂ ", "Level_II_Description":"Science that deals with the characteristics, effects, and uses of drugs and their interactions with living organisms.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NCI-GLOSS", "Alt_Identifier_CUI":"NCI-GLOSS", "Level_II_Alt_Description":"The study of the origin, chemistry, and uses of drugs and their effects on the body.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Pharmacology is the study of the biological effects of a drug and its interaction with living systems. After studying the in vitro and in vivo pharmacology of various lead compounds, researchers conduct additional pharmacology studies with chosen compounds for preclinical and clinical research.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/pharmacology", "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":52, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1131, "submap_id":2, "object_id":53, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"GLP Toxicology", "label_name":"GLP Toxicology", "group_name":"Lead Optimization", "reference_synonym":"Toxicology", "identifier_CUI":"C0040541", "NCI_thesaurus_code":null, "semantic_type":"Biomedical Occupation or Discipline", "sematic_type_code":"T091", "Level_II_Source":"NCIÂ ", "Level_II_Description":"Toxicology is the branch of pharmacology that deals with the nature and effects and treatments of poisons.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"CDISC", "Alt_Identifier_CUI":"CDISC", "Level_II_Alt_Description":"Toxicology is the study of the adverse effects of chemical, physical or biological agents on people, animals, and the environment.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"Nature.com search", "Alt_Description2":"Toxicology is the scientific discipline concerned with the detection, evaluation and prevention of the toxic effects of substances that humans are exposed to. It has a key role in the development of new drugs, which are evaluated for potential toxic effects in preclinical studies, clinical trials and post-marketing studies with the aim of ensuring that their benefits outweigh their risks.", "Alt_URL2":"https://www.nature.com/subjects/toxicology?WT.ac=search_subjects_toxicology", "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":53, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1132, "submap_id":2, "object_id":54, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Long-Term Toxicology; Reproductive Toxicology; Carcinogenesis, etc.", "label_name":"Toxicology; Long-Term, Reproductive, Cancer, etc.", "group_name":"Lead Optimization", "reference_synonym":"Toxicology", "identifier_CUI":"C0040541", "NCI_thesaurus_code":null, "semantic_type":"Biomedical Occupation or Discipline", "sematic_type_code":"T091", "Level_II_Source":"NCIÂ ", "Level_II_Description":"Toxicology is the branch of pharmacology that deals with the nature and effects and treatments of poisons.", "Level_II_Link":null, "Level_II_Synonym":"Chemical Carcinogenesis", "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Long-term toxicology refers to studies on the toxic effects of a compound when it is administered over an extended period of time. Long-term toxicology studies usually use at least two animal species and three different dose levels. The duration of the study is proportional to the expected clinical use, and testing includes behavioral observations and basic physical examinations", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/toxicology", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":54, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1133, "submap_id":2, "object_id":55, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Late CMC (e.g. Formulation)", "label_name":"Late CMC; Formulation", "group_name":"Lead Optimization", "reference_synonym":"Chemistry, Manufacturing and Control", "identifier_CUI":"C0524527", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCIÂ ", "Level_II_Description":"The act or process of developing or preparing a mixture of ingredients to create a desired end drug product, such as a specific flavor, aroma, or polymer; or the desired final drug product itself; also, a listing of the ingredients and composition of the dosage form.", "Level_II_Link":null, "Level_II_Synonym":"Drug Formulation Process", "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Chemistry, manufacturing and control refers to a set of data containing detailed information on the chemical structure of the investigational compound, the stability of the compound, how it was produced and the quality controls used in manufacturing. This data must be submitted to regulatory agencies before the compound can be used in humans", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/manufacture", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":55, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1134, "submap_id":2, "object_id":56, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Sustained Product Availability", "label_name":"Sustained Product Availability", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Sustained product availability ensures consistent drug accessibility. It is important to confirm the adequacy and availability of all drug ingredients, manufacturing capacity and delivery methods before a therapy is made available to the public.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/product", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":"Bridging Interventional Development Gaps (BrIDGs) Program", "NCATS_Program_2_Label":"New Drug Development", "NCATS_Program_Link_2":"https://ncats.nih.gov/bridgs", "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":56, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1135, "submap_id":2, "object_id":57, "function":"Persona", "sub_function":"investigator", "relationship":null, "submap_node_parent_id":77, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Researcher / Investigator", "label_name":"Principle Investigator", "group_name":"Clinical Research", "reference_synonym":"Investigator; Principal Investigator", "identifier_CUI":"C1521895", "NCI_thesaurus_code":null, "semantic_type":"Professional or Occupational Group; T097", "sematic_type_code":"T097", "Level_II_Source":"NCI", "Level_II_Description":"The name of the investigator who is responsible for defined aspects of a nonclinical study, as specified in the study protocol.", "Level_II_Link":null, "Level_II_Synonym":"Clinical Investigators", "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator. The principal investigator is the person who is responsible for the scientific and technical direction of the entire clinical study.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"The principal researcher or investigator is the lead scientist for a specific scientific research project. The principal investigator will head the lab and lead a research group. As it pertains to medicine, the principal investigator will lead in a laboratory or clinical setting, and is responsible for completion of the project. He or she is also responsible for reporting to a funding agency. Principal investigators can conceive of or be assigned to projects.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/researcher", "NCATS_Program_1":"NCATS Clinical and Translational Science Awards (CTSA) Program", "NCATS_Program_1_Label":"CTSA Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ctsa", "NCATS_Program_2":"Rare Diseases Clinical Research Network (RDCRN)", "NCATS_Program_2_Label":"Rare Disease Network", "NCATS_Program_Link_2":"https://ncats.nih.gov/rdcrn", "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":"Rare Disease Resources", "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":57, "parent":77, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1136, "submap_id":2, "object_id":58, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":61, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Qualified Investigator and Study Staff", "label_name":"Qualified Investigator and Study Staff", "group_name":"Clinical Research", "reference_synonym":"Research Personnel", "identifier_CUI":"C0035173", "NCI_thesaurus_code":null, "semantic_type":"Professional or Occupational Group; T097", "sematic_type_code":"T097", "Level_II_Source":"NETS", "Level_II_Description":"A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at the trial site, the investigator is the responsible leader of the team and may be called the principle investigator.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Qualified investigators and study staff oversee the entire clinical trial. A principle investigator has the sole responsibility of overseeing all the research. Study staff may be responsible for certain tasks within the study. Investigators and study staff are deemed qualified to conduct the study by their level of education, training and experience in performing their assigned task.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/study_staff", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":58, "parent":61, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1137, "submap_id":2, "object_id":59, "function":"Resource", "sub_function":"Service", "relationship":null, "submap_node_parent_id":61, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Contractual & Legal Agreements (Sponsored Contracting)", "label_name":"Contractual & Legal Agreements (Sponsored Contracting)", "group_name":"Clinical Research", "reference_synonym":"Clinical Trial Committee Member", "identifier_CUI":"C4086190", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NCI", "Level_II_Description":"A written agreement between a clinical trial independent committee member and sponsor or other party that defines any arrangement on delegation and distribution of tasks and obligations.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Contractual & legal agreements formally document the responsibilities of different professionals involved in clinical research.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/agreements", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":59, "parent":61, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1138, "submap_id":2, "object_id":60, "function":"Resource", "sub_function":"Service", "relationship":null, "submap_node_parent_id":61, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Study Sponsor", "label_name":"Study Sponsor", "group_name":"Clinical Research", "reference_synonym":"Clinical Study Sponsor", "identifier_CUI":"C2347796", "NCI_thesaurus_code":null, "semantic_type":"Organization; T092", "sematic_type_code":"T092", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"An entity that is responsible for the initiation, management, and/or financing of a clinical study. [NCI]", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA Glossary of Terms: For Patients", "Alt_Identifier_CUI":"FDA Glossary of Terms: For Patients", "Level_II_Alt_Description":"Clinical trials are sponsored or funded by various organizations or individuals, including physicians, foundations, medical institutions, voluntary groups, and pharmaceutical companies, as well as Federal agencies such as NIH, FDA, the Department of Defense, and the Department of Veterans Affairs.", "Level_II_alt_Link":"https://www.fda.gov/ForPatients/ucm410359.htm#I-1", "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Study sponsors are the companies, agencies, universities or organizations responsible for overseeing a clinical research project. They are responsible for managing all of the processes involved in clinical research, including recruiting participants and qualified study staff, obtaining all necessary IRB approval, and managing all contractual and legal agreements.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/sponsor", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":60, "parent":61, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1139, "submap_id":2, "object_id":61, "function":"Resource", "sub_function":"Service", "relationship":null, "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Clinical Trial Planning & Preparation", "label_name":"Study Preparation Consultation Services", "group_name":"Clinical Research", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Clinical trial preparation and planning is the process of developing a protocol or action plan for conducting clinical research. It describes the what, who, how and why of the study. Clinical trial preparation and planning also involves determining the eligibility criteria and strategies for participant enrollment.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/nets/content/preparation", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Rare Disease Resources", "NCATS_Program_1_Label":"Rare Disease Resources", "NCATS_Program_Link_1":"https://rarediseases.info.nih.gov/toolkit", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":61, "parent":119, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1140, "submap_id":2, "object_id":62, "function":"Resource", "sub_function":"Service", "relationship":null, "submap_node_parent_id":61, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Regulatory Compliance Strategy Service", "label_name":"Regulatory Compliance Strategy Service", "group_name":"Clinical Research", "reference_synonym":"yes", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCATS", "Level_II_Description":"A thorough plan to ensure that all aspects of a drug development program comply with the applicable rules, regulations and policies established by the Food and Drug Administration to ensure the safety and efficacy of medicines.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"NCATS Clinical and Translational Science Awards (CTSA) Program", "NCATS_Program_1_Label":"CTSA Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ctsa", "NCATS_Program_2":"Rare Diseases Clinical Research Network (RDCRN)", "NCATS_Program_2_Label":"Rare Disease Network", "NCATS_Program_Link_2":"https://ncats.nih.gov/rdcrn", "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":"Rare Disease Resources", "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":62, "parent":61, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1141, "submap_id":2, "object_id":63, "function":"List", "sub_function":"Database Clinical", "relationship":"Database Clinical", "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Clinical Cohorts (Subject Management)", "label_name":"Clinical Cohorts", "group_name":"Clinical Research", "reference_synonym":"Group/cohort", "identifier_CUI":"C0599755", "NCI_thesaurus_code":null, "semantic_type":"Population Group; T098", "sematic_type_code":"T098", "Level_II_Source":"NCI", "Level_II_Description":"A group of individuals who share a common trait, such as birth year. In medicine, a cohort is a group that is part of a clinical trial or study and is observed over a period of time.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"A clinical cohort is a group of individuals that share a common characteristic or disease. Grouping individuals with a shared characteristic or disease can be helpful in organizing and recruiting participants that are eligible for a particular research study or clinical trial.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/cohorts", "NCATS_Program_1":"Rare Disease Resources", "NCATS_Program_1_Label":"Rare Disease Resources", "NCATS_Program_Link_1":"https://rarediseases.info.nih.gov/toolkit", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":63, "parent":119, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1142, "submap_id":2, "object_id":64, "function":"List", "sub_function":"Database Clinical", "relationship":"Database Clinical", "submap_node_parent_id":65, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Biospecimens", "label_name":"Biospecimens", "group_name":"Clinical Research", "reference_synonym":"Biospecimen", "identifier_CUI":"C2347026", "NCI_thesaurus_code":null, "semantic_type":"Conceptual Entity; T077", "sematic_type_code":"T077", "Level_II_Source":"NETS", "Level_II_Description":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Biospecimens are biological samples collected from humans such as blood samples, tumor samples, or other tissues. When someone with a disease or condition has a biopsy, surgery, or other procedure, often a small amount of the specimen taken can be stored and used for later research. The specimens are used in biomedical research to learn about how disease affects the human body.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/biospecimens", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":64, "parent":65, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1143, "submap_id":2, "object_id":65, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Natural History & Epidemiological Studies", "label_name":"Natural History & Epidemiological Studies", "group_name":"Clinical Research", "reference_synonym":"Natural history studies", "identifier_CUI":"C0175860", "NCI_thesaurus_code":null, "semantic_type":"Occupation or Discipline; T090", "sematic_type_code":"T090", "Level_II_Source":"NETS", "Level_II_Description":"A study that follows a group of people over time who have, or are at risk of developing, a specific medical condition or disease. A natural history study collects health information in order to understand how the medical condition or disease develops and how to treat it.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Natural history studies are studies that observe individuals with a certain disease or people who are at high risk of developing the disease. The purpose of natural history studies is to understand and characterize the normal progression of a disease or condition. More specifically, natural history studies can help researchers to gain an understanding the etiology, range of manifestations, and progression of rare diseases. ", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/studies", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":65, "parent":119, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1144, "submap_id":2, "object_id":66, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":65, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Registries/EMRs", "label_name":"Registries / EMRs", "group_name":"Clinical Research", "reference_synonym":"Registries", "identifier_CUI":"C0597185", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NETS", "Level_II_Description":"Â facilities that register, collect, store, and distribute information about patients or diseases; may also be used for information systems about patients or diseases; for genetic disordersÂ ", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Registries are databases of information on individuals affected by a certain disease or condition. The type of data included in registries will vary depending on the purpose of the registry. Contact registries, which are useful for organizing the disease community and clinical cohorts, include names, contact information, and perhaps some demographics. Registries that are intended to be used for research will also include some clinical information, such as age of onset, symptoms, medical images or test results. The type of information included in a registry will vary for each disease.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/registries", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Rare Diseases Registry (RaDaR) Program ", "NCATS_Program_1_Label":"Rare Disease Registries", "NCATS_Program_Link_1":"https://ncats.nih.gov/radar", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":66, "parent":65, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1145, "submap_id":2, "object_id":67, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":61, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Outcomes, Rates, and Severity Measures", "label_name":"Outcomes, Severity Measures", "group_name":"Clinical Research", "reference_synonym":"Outcome measure; Primary outcome measure", "identifier_CUI":"C0086749", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"HL7V3.0", "Level_II_Description":"Operational activities conducted for the purposes of assessing the results of an activity, product, or service", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure. In a clinical study's protocol, the primary outcome measure is the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one. The secondary outcome measure is the planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":"Outcome measures", "Alt_Source2":"NETS Map", "Alt_Description2":"Outcomes measures evaluate the impact of therapeutic intervention. They are used to evaluate the benefits and drawbacks of investigational drugs or therapies.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/outcomes", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":67, "parent":61, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1146, "submap_id":2, "object_id":68, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":61, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Population-Specific & Events from Existing Therapy", "label_name":"Population- Specific & Events", "group_name":"Clinical Research", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Therapeutic or Preventive Procedure; T061", "sematic_type_code":"T061", "Level_II_Source":"NCATS", "Level_II_Description":"Outcomes of specific patient populations after therapeutics interventions", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":68, "parent":61, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1147, "submap_id":2, "object_id":69, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":63, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Cohort Identification of Target Population", "label_name":"Cohort Identification & Accrual Feasibility", "group_name":"Clinical Research", "reference_synonym":"Cohort Studies", "identifier_CUI":"C0009247", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"NCI", "Level_II_Description":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).", "Level_II_Link":null, "Level_II_Synonym":"Target Population", "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":"Identification of subpopulations", "Alt_Source2":"NETS Map", "Alt_Description2":"Identification of subpopulations is the process of grouping the individuals affected by a disease by their commonalities. Identification of subpopulations helps us to understand why different individuals respond differently to the same therapy or why different individuals with the same disease exhibit different symptoms.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/subpopulations", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":69, "parent":63, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1148, "submap_id":2, "object_id":70, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":83, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Therapeutic and Clinical Endpoints", "label_name":"Therapeutic and Clinical Endpoints", "group_name":"Clinical Research", "reference_synonym":"End Point", "identifier_CUI":"C2349179", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"NETS", "Level_II_Description":"Health events that lead to completion or termination of follow-up of an individual in a trial or cohort study, for example, death or major morbidity, particularly related to the study question.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"A clinical and therapeutic endpoint refers to the occurrence of an outcome (that is, a sign or a symptom) that constitutes one of the targets of the trial. They are distinct measurements of disease characteristics that reflect the effect of a therapeutic intervention, in terms of how recipients of a drug or therapy feel, function, or survive. These endpoints may also signal a point at which a participant should withdraw from a trial or study.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/endpoint", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":70, "parent":83, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1149, "submap_id":2, "object_id":71, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":77, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"IRB Review", "label_name":"IRB Review", "group_name":"Clinical Research", "reference_synonym":"Institutional Review Board", "identifier_CUI":"C2347793", "NCI_thesaurus_code":null, "semantic_type":"Functional Concept; T169", "sematic_type_code":"T169", "Level_II_Source":"Wikipedia", "Level_II_Description":"AnÂ institutional review boardÂ (IRB), also known as anÂ independent ethics committeeÂ (IEC),Â ethical review boardÂ (ERB), orÂ research ethics boardÂ (REB), is a type ofÂ committeeÂ that appliesÂ research ethicsÂ by reviewing theÂ methodsÂ proposed forÂ researchÂ to ensure that they areÂ ethical. Such boards are formally designated to approve (or reject), monitor, and reviewÂ biomedicalÂ andÂ behavioralÂ research involvingÂ humans. They often conduct some form ofÂ risk-benefit analysisÂ in an attempt to determine whether or not research should be conducted. [1]Â The purpose of the IRB is to assure that appropriate steps are taken to protect the rights andÂ welfareÂ of humans participating as subjects in a research study. Along with developed countries, many developing countries have established national, regional or local Institutional Review Boards in order to safeguard ethical conduct of research concerning both national and international norms, regulations or codes", "Level_II_Link":"https://en.wikipedia.org/wiki/Institutional_review_board", "Level_II_Synonym":"Clinical Study Site Pending IRB Approval", "Level_II_Alt_Source":"FDA Glossary of Terms: For Patients", "Alt_Identifier_CUI":"FDA Glossary of Terms: For Patients", "Level_II_Alt_Description":"An Institutional Review Board (IRB) refers to any board, committee, or other group formally designated by an institution to review, to approve the initiation of, and to conduct periodic review of, biomedical research involving human subjects. The primary purpose of such review is to assure the protection of the rights and welfare of the human subjects.", "Level_II_alt_Link":"https://www.fda.gov/ForPatients/ucm410359.htm#I-1", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":71, "parent":77, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1150, "submap_id":2, "object_id":72, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":77, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"IRB Approval", "label_name":"IRB Approval", "group_name":"Clinical Research", "reference_synonym":"Institutional Review Board Approval", "identifier_CUI":"C2346499", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NETS", "Level_II_Description":"A document containing the determination of the Institutional Review Board (IRB) that the clinical study with human subject participation has been reviewed and may be conducted at a particular study site within the constraints set forth by the IRB and other institutional and federal requirements. The regulations require that an IRB conduct continuing review of research at intervals appropriate to the degree of risk, but not less than once a year.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"An institutional review board (IRB) is a committee that protects the rights and privacy of the individuals that participate in studies. Typically IRBs are composed of a handful of health professionals and researchers that are not involved in the proposed research, who can serve as an objective judge of the potential benefits and harms of a proposed research project. They review all documentation involved in research studies involving humans, including research protocols, informed consent documents, any materials developed for recruiting research participants, and security measures taken to protect sensitive participant data. Any research that involves human subjects must obtain IRB approval or an exemption before beginning the study. ", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/IRB", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":72, "parent":77, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1151, "submap_id":2, "object_id":73, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":63, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Recruitment", "label_name":"Recruit / Enroll", "group_name":"Clinical Research", "reference_synonym":"Recruitment", "identifier_CUI":"C2949735", "NCI_thesaurus_code":null, "semantic_type":"Activity; T052", "sematic_type_code":"T052", "Level_II_Source":"NETS", "Level_II_Description":"The process of enrolling, enlisting, or adding individuals to a group.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Recruitment is the identification and enrollment of participants for a study. Typically, participants must fit certain criteria in order to be recruited for a particular study. During the recruitment process potential participants will go through the process of informed consent, in which they learn more about the study and their rights as study participants. Investigators can recruit within specific communities or the general population through outreach and advertisement.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/recruitment", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":73, "parent":63, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1152, "submap_id":2, "object_id":74, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":77, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Informed Consent", "label_name":"Informed Consent", "group_name":"Clinical Research", "reference_synonym":"Informed Consent", "identifier_CUI":"C0021430", "NCI_thesaurus_code":null, "semantic_type":"Regulation or Law; T089", "sematic_type_code":"T089", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA Glossary of Terms: For Patients", "Alt_Identifier_CUI":"FDA Glossary of Terms: For Patients", "Level_II_Alt_Description":"When a participant provides informed consent, it means that he or she has learned the key facts about a research study and agrees to take part in it. ", "Level_II_alt_Link":"https://www.fda.gov/ForPatients/ucm410359.htm#I-1", "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"The goal of informed consent is to provide people with sufficient information so they can make the most informed decision possible about whether or not to continue participation in clinical research. While consenting an individual, the clinical study in question is summarized and the rights of the participant are stated. Often individuals sign a document containing this information to officially confirm they have consented to the research.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/consent", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":74, "parent":77, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1153, "submap_id":2, "object_id":75, "function":"Resource", "sub_function":"People", "relationship":null, "submap_node_parent_id":63, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Participant or Health Subject Enrollment", "label_name":"Participant / Study Patients", "group_name":"Clinical Research", "reference_synonym":"Participant enrollment", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCATS", "Level_II_Description":"People take part in clinical trials for many reasons. Healthy volunteers say they take part to help others and to contribute to moving science forward. People with an illness or disease also take part to help others, but also to possibly receive the newest treatment and to have added (or extra) care and attention from the clinical trial staff. Clinical trials offer hope for many people and a chance to help researchers find better treatments for others in the future", "Level_II_Link":"https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics", "Level_II_Synonym":"Enrollment in clinical trial", "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"A participant is someone who voluntarily takes part in a research study. Participant enrollment occurs when an individual meets all involvement criteria for a study and agrees to participate (through informed consent). This participant can now be a part of the study.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/enrollment", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":75, "parent":63, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1154, "submap_id":2, "object_id":76, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Randomized Clinical Trial (RTC)", "label_name":"Randomized Clinical Trial (RTC)", "group_name":"Clinical Research", "reference_synonym":"Clinical Trials", "identifier_CUI":"C0008976", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"MSH", "Level_II_Description":"Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":76, "parent":119, "color":"#028475", "nodeLocContent":[ {"ObjectId":76, "name":"clinical2nd", "display_name":null, "uri":null, "uri_display_name":null, "description":null, "poc_first_name":"cli2nd", "poc_last_name":"last", "poc_email":"clinical2nd@test.com", "street_address":"903 South 4th Street", "city":"Hamilton", "state":"MT", "zip":"59840", "lat":46.2379626, "lng":-114.1625192},{"ObjectId":76, "name":"Clinical Trials", "display_name":"Clinical Trials", "uri":null, "uri_display_name":null, "description":"Clinical Trials", "poc_first_name":"JohnTest", "poc_last_name":"Doe", "poc_email":"john@test.com", "street_address":"123A 7th Avenue", "city":"New York", "state":"NY", "zip":"10011", "lat":40.7406309, "lng":-73.9979491} ], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1155, "submap_id":2, "object_id":77, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Preapproval Clinical Trials", "label_name":"Preapproval Clinical Trials", "group_name":"Clinical Research", "reference_synonym":"Early Phase 1; Phase 0", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"ClinicalTrials.gov Glossary", "Level_II_Description":"A phase of research used to describe exploratory trials conducted before traditional phase 1 trials to investigate how or whether a drug affects the body. They involve very limited human exposure to the drug and have no therapeutic or diagnostic goals (for example, screening studies, micro dose studies).", "Level_II_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"NCATS Clinical and Translational Science Awards (CTSA) Program", "NCATS_Program_1_Label":"CTSA Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ctsa", "NCATS_Program_2":"Rare Diseases Clinical Research Network (RDCRN)", "NCATS_Program_2_Label":"Rare Disease Network", "NCATS_Program_Link_2":"https://ncats.nih.gov/rdcrn", "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":"Rare Disease Resources", "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":77, "parent":119, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1156, "submap_id":2, "object_id":78, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":76, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Phase I Clinical Trial", "label_name":"Phase I Clinical Trial", "group_name":"Clinical Research", "reference_synonym":"Clinical Trial, Phase I", "identifier_CUI":"C0282459", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"MSH", "Level_II_Description":"Work that is the report of a pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the United States or a foreign country.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":"Phase I Clinical Trials (PK, Safety, Dose)", "Alt_Source2":"NETS Map", "Alt_Description2":"In Phase I clinical trials researchers test a new drug or treatment on a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects: in other words, they study its safety and dose. The pharmacokinetics (PK) of the drug or therapy - are examined as well. The participants in Phase I trials are healthy or unaffected volunteers.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/phase_I", "NCATS_Program_1":"NCATS Clinical and Translational Science Awards (CTSA) Program", "NCATS_Program_1_Label":"CTSA Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ctsa", "NCATS_Program_2":"Rare Diseases Clinical Research Network (RDCRN)", "NCATS_Program_2_Label":"Rare Disease Network", "NCATS_Program_Link_2":"https://ncats.nih.gov/rdcrn", "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":"Rare Disease Resources", "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":78, "parent":76, "color":"#028475", "nodeLocContent":[ {"ObjectId":78, "name":"ARUP Laboratories", "display_name":"ARUP Laboratories", "uri":"https://www.aruplab.com/trials", "uri_display_name":null, "description":"ARUP Laboratories is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials.", "poc_first_name":"Jonathan", "poc_last_name":"Lowe", "poc_email":"jonathan.lowe@aruplab.com", "street_address":"500 Chipeta Way", "city":"Salt Lake City", "state":"UT", "zip":"84108", "lat":40.7570702, "lng":-111.8252594} ], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":true},
{"submap_nodes_id":1157, "submap_id":2, "object_id":79, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":76, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Phase II Clinical Trial", "label_name":"Phase II Clinical Trial", "group_name":"Clinical Research", "reference_synonym":"Clinical Trial, Phase II", "identifier_CUI":"C1096779", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"MSH", "Level_II_Description":"Work that is a report of a pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the United States or a foreign country.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":"Phase II Clinical Trials (Safety, POCC, Dose)", "Alt_Source2":"NETS Map", "Alt_Description2":"Phase II clinical trials are studies to evaluate the effectiveness of an investigational drug or therapy and observe short-term side effects and risks. They continue the study of drug safety and dose, and they also aim to provide proof of clinical concept (POCC) - that is, proof that the drug has the desired effect on individuals with a specific condition. This means that, unlike Phase I trials, Phase II trials include participants affected by the disease or condition of interest as opposed to the unaffected volunteers utilized in Phase I. Phase II clinical trials usually last around two years.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/phase_II", "NCATS_Program_1":"NCATS Clinical and Translational Science Awards (CTSA) Program", "NCATS_Program_1_Label":"CTSA Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ctsa", "NCATS_Program_2":"Rare Diseases Clinical Research Network (RDCRN)", "NCATS_Program_2_Label":"Rare Disease Network", "NCATS_Program_Link_2":"https://ncats.nih.gov/rdcrn", "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":"Rare Disease Resources", "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":79, "parent":76, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1158, "submap_id":2, "object_id":80, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":76, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Phase III Clinical Trial", "label_name":"Phase III Clinical Trial", "group_name":"Clinical Research", "reference_synonym":"Clinical Trials, Phase III", "identifier_CUI":"C0282461", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"MSH", "Level_II_Description":"Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"A phase of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":"Phase III Clinical Trials (Safety, Efficacy)", "Alt_Source2":"NETS Map", "Alt_Description2":"Phase III clinical trials are large studies which confirm drug safety and efficacy. They contain a greater number of participants than Phase II trials so that safety and efficacy can be validated in a larger population. The trials almost always randomly assign participants to one of two groups, the control group or the treatment group. Phase III trials usually include participants of different race, ethnicity and gender, in order to see how a drug acts on a diverse group of people.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/phase_III", "NCATS_Program_1":"NCATS Clinical and Translational Science Awards (CTSA) Program", "NCATS_Program_1_Label":"CTSA Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ctsa", "NCATS_Program_2":"Rare Diseases Clinical Research Network (RDCRN)", "NCATS_Program_2_Label":"Rare Disease Network", "NCATS_Program_Link_2":"https://ncats.nih.gov/rdcrn", "NCATS_Program_3":"NCATS Toolkit for Patient-Focused Therapy Development", "NCATS_Program_3_Label":"Rare Disease Resources", "NCATS_Program_Link_3":"https://rarediseases.info.nih.gov/toolkit", "bottleneck":null, "key":80, "parent":76, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1159, "submap_id":2, "object_id":81, "function":"List", "sub_function":"Database Clinical", "relationship":"Database Clinical", "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Clinical Trial Data", "label_name":"Clinical Trial Data", "group_name":"Clinical Research", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCBI", "Level_II_Description":"During the course of a clinical trial, different types of data are collected, transformed into analyzable data sets to address specific research questions, and used to generate various publications and reports for different audiences. Data are generated at nearly every stage of the clinical trial life cycle, from the initial protocol and statistical analysis plan prepared prior to registration, to the collection of baseline participant data at participant enrollment, to the analysis of the analyzable data set. ", "Level_II_Link":"https://www.ncbi.nlm.nih.gov/books/NBK286004/", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":81, "parent":119, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1160, "submap_id":2, "object_id":82, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":81, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Translational Pharmacology", "label_name":"Translational Pharmacology", "group_name":"Clinical Research", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Frontiers in Pharmacology", "Level_II_Description":"Translational pharmacology is the field of science focused on improving the predictive value of the tools that are used to qualify the efficacy of a drug candidate.", "Level_II_Link":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243817/", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":82, "parent":81, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1161, "submap_id":2, "object_id":83, "function":"Resource", "sub_function":"Service", "relationship":null, "submap_node_parent_id":119, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Clinical Program & Trial Design", "label_name":"Clinical Program & Trial Design", "group_name":"Clinical Research", "reference_synonym":"Clinical Trials Design", "identifier_CUI":"C1516636", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NETS", "Level_II_Description":"he detailed planning of studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"The protocol that is developed for a clinical trial or study to test a hypothesis. It addresses factors such as the number of participants and controls necessary for a valid study.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":83, "parent":119, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1162, "submap_id":2, "object_id":84, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":83, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"FDA Review", "label_name":"FDA Review", "group_name":"Clinical Research", "reference_synonym":"Regulatory review", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Governmental or Regulatory Activity; T064", "sematic_type_code":"T064", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"A review is the basis of FDA's decision to approve an application. It is a comprehensive analysis of clinical trial data and other information prepared by FDA drug application reviewers. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology.", "Level_II_Link":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":84, "parent":83, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1163, "submap_id":2, "object_id":85, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":76, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Reevaluate or Discontinue", "label_name":"Reevaluate or Discontinue", "group_name":"Clinical Research", "reference_synonym":"Request for Withdrawal of Application Approval", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Regulation or Law; T089", "sematic_type_code":"T089", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"If new data or evidence that shows an approved drug has dangerous risks associated with its use or is ineffective, the drug may beÂ re-evaluated by the health administration. They will look at the new evidence and decide whether the evidence is valid and if the drug should beÂ discontinued. A drug is discontinued when the health administration revokes their approval or decides to stop a clinical trial of the drug. When this happens, the compound will no longer be available for use in humans.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/re-evaluate", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":"If new data or evidence that shows an approved drug has dangerous risks associated with its use or is ineffective, the drug may be re-evaluated by the health administration. They will look at the new evidence and decide whether the evidence is valid and if the drug should be discontinued. A drug is discontinued when the health administration revokes their approval or decides to stop a clinical trial of the drug. When this happens, the compound will no longer be available for use in humans.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/re-evaluate", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":85, "parent":76, "color":"#028475", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1164, "submap_id":2, "object_id":86, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Regulatory Review", "label_name":"Regulatory Review", "group_name":"Regulatory Review", "reference_synonym":"FDA review", "identifier_CUI":"C3242240", "NCI_thesaurus_code":null, "semantic_type":"Idea or Concept; T078", "sematic_type_code":"T078", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"A review is the basis of FDA's decision to approve an application. It is a comprehensive analysis of clinical trial data and other information prepared by FDA drug application reviewers. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology", "Level_II_Link":"https://www.fda.gov/drugs/informationondrugs/ucm079436.htm#R", "Level_II_Synonym":null, "Level_II_Alt_Source":"Drugs@FDA Glossary", "Alt_Identifier_CUI":"Drugs@FDA Glossary", "Level_II_Alt_Description":"A review is the basis of FDA's decision to approve an application. It is a comprehensive analysis of clinical trial data and other information prepared by FDA drug application reviewers. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology.", "Level_II_alt_Link":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":86, "parent":116, "color":"#477700", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1165, "submap_id":2, "object_id":87, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":86, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"IND Investigational New Drug (IND) Application", "label_name":" Investigational New Drug (IND) Application", "group_name":"Regulatory Review", "reference_synonym":"IND", "identifier_CUI":"C0013230", "NCI_thesaurus_code":null, "semantic_type":"Pharmacologic Substance; T121", "sematic_type_code":"T121", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"A substance that has been tested in a laboratory and has gotten approval from the U.S. Food and Drug Administration (FDA) to be tested in people. An experimental drug may be approved by the FDA for use in one disease or condition but be considered investigational in other diseases or conditions.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA: Investigational New Drug (IND) Application", "Alt_Identifier_CUI":"FDA: Investigational New Drug (IND) Application", "Level_II_Alt_Description":"Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA. An Investigator IND is submitted by a physician who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed.  A physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population. The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies; Manufacturing Information; and Clinical Protocols and Investigator Information. Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials.  During this time, FDA  has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.", "Level_II_alt_Link":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm", "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"An investigational new drug (IND) application is an application that must be submitted to the FDA to obtain permission to begin a clinical trial. An IND application is submitted by the clinical trial sponsor and must include documentation of the pharmacology and toxicology studies demonstrating that the compound has proven safe in animal testing. It will also contain manufacturing information, clinical protocols for the proposed clinical trial, and information on the study investigators and staff. This report must be submitted to the FDA before human testing may begin.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/ind", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":87, "parent":86, "color":"#477700", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1166, "submap_id":2, "object_id":88, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":87, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Protocol Reporting, Meeting, Amendments", "label_name":"Meetings, Amendments, Reporting", "group_name":"Regulatory Review", "reference_synonym":"Amendment", "identifier_CUI":"C0680532", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NETS", "Level_II_Description":"Â A change in a document made by correction, adding, substituting or omitting a certain part. Amendments are the mechanism of changes introduction, further development and improvement of previously submitted or approved clinical study protocols and proposals.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"In the United States, FDA reporting meetings are conducted after the completion of an IND application but prior to the official ruling on an NDA. They provide the sponsor with the opportunity to discuss their application with regulatory officials and make the necessary updates. Members of the community, including patients, advocates, and researchers, are also allowed to offer their perspective on an investigational compound to regulatory officials.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/health_authorities", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":88, "parent":87, "color":"#477700", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1167, "submap_id":2, "object_id":89, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":87, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Patient Perspective", "label_name":"Patient Perspective", "group_name":"Regulatory Review", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Health Care Activity; T058", "sematic_type_code":"T058", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"Patientsâ€™ experiences, perspectives, needs, and priorities must be captured and meaningfully incorporated into drug development and evaluation. As experts in what it is like to live with their condition, patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation.", "Level_II_Link":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm579400.htm", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":89, "parent":87, "color":"#477700", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1168, "submap_id":2, "object_id":90, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":86, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"NDA or BLA New Drug Application", "label_name":"NDA or BLA Application", "group_name":"Regulatory Review", "reference_synonym":"NDA", "identifier_CUI":"C2347344", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NCI", "Level_II_Description":"A type of application which a pharmaceutical manufacturer or its agent requests permission from the United States Food and Drug Administration (FDA) for a license to market a drug for one or more specified indications; besides a chemical and pharmacologic description of the drug, the application must show the results of clinical trials conducted with respect to the indication for which a license is requested as a New Drug Application (NDA) or a Biologics License Applications (BLA)", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"Drugs@FDA Glossary", "Alt_Identifier_CUI":"Drugs@FDA Glossary", "Level_II_Alt_Description":"When the sponsor of a new drug believes that enough evidence on the drug's safety and effectiveness has been obtained to meet FDA's requirements for marketing approval, the sponsor submits to FDA a new drug application (NDA). The application must contain data from specific technical viewpoints for review, including chemistry, pharmacology, medical, biopharmaceutics, and statistics. If the NDA is approved, the product may be marketed in the United States. ", "Level_II_alt_Link":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page", "Alt_Synonym2":"NDA or BLA", "Alt_Source2":"NETS Map", "Alt_Description2":"An NDA, or \"New Drug Application,\" is the formal method for a drug manufacturer to apply for FDA approval to begin sale and marketing of a new pharmaceutical in the US. An NDA contains every piece of information about a drug, from its chemical composition to its packaging to the results from its clinical trials. ", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/NDA", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":90, "parent":86, "color":"#477700", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1169, "submap_id":2, "object_id":92, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":90, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"NDA Rejection - Complete Response Letter", "label_name":"Rejection - Complete Response Letter", "group_name":"Regulatory Review", "reference_synonym":"Rejected Application", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Regulation or Law; T089", "sematic_type_code":"T089", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"A rejected application is an IND, NDA or BLA that is rejected by the FDA. Application can be rejected if they fail to provide evidence that the investigational compound is safe or effective. The FDA might also require supplemental information or further study before deciding to accept or reject the application.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/rejected", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":92, "parent":90, "color":"#477700", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1170, "submap_id":2, "object_id":93, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":90, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"NDA or BLA Approval", "label_name":"FDA Approved Therapy", "group_name":"Regulatory Review", "reference_synonym":"NDA Approval", "identifier_CUI":"C2700205", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NCI", "Level_II_Description":"A written regulatory communication from FDA to an applicant, who submitted request to the agency to approve marketing or to license medical product, stating that the agency can approve the application or abbreviated application if specific additional information or material is submitted or specific conditions are met. An approvable letter does not constitute approval of any part of an application or abbreviated application and does not permit marketing of the drug that is the subject of the application or abbreviated application. The letter often lists minor deficiencies in the product documentation that have to be corrected, often involves labeling changes, and possibly requests sponsor commitment to do post-approval studies.", "Level_II_Link":null, "Level_II_Synonym":"FDA Approval", "Level_II_Alt_Source":"Drugs@FDA Glossary", "Alt_Identifier_CUI":"Drugs@FDA Glossary", "Level_II_Alt_Description":"An official communication from FDA to a drug application (NDA, BLA, or ANDA) sponsor that allows the commercial marketing of the product.", "Level_II_alt_Link":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page", "Alt_Synonym2":"Approved therapy", "Alt_Source2":"NETS Map", "Alt_Description2":"An approved therapy is a medical product that has proven to be safe and effective in clinical trials and has therefore received FDA marketing approval.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/therapy", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":93, "parent":90, "color":"#477700", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1171, "submap_id":2, "object_id":94, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":96, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Post Approval Data Collection", "label_name":"Post Approval Data Collection", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Regulation or Law; T089", "sematic_type_code":"T089", "Level_II_Source":"NCATS", "Level_II_Description":"This data is collected after a drug has received regulatory approval and is on the market in order to look for side effects that were not seen in earlier trials and may also study how well a new drug works over a long period of time.", "Level_II_Link":"https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM393994.pdf", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":"FDA Post-Approval Safety Data Management Definitions", "Level_II_alt_Link":"https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073106.pdf", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":94, "parent":96, "color":"#07534d", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1172, "submap_id":2, "object_id":95, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":96, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Post-Marketing Knowledge", "label_name":"Post-Marketing Knowledge", "group_name":"Post Marketing", "reference_synonym":"Post-market surveillance", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"The process by which a drugâ€™s safety is monitored on an ongoing basis after a drug is approved by FDA. Post-market surveillance looks to identify problems that were not observed or recognized before approval and any problems that may arise because a drug may not be used as described in the drug labeling, or because a drug is being manufactured incorrectly.", "Level_II_Link":"https://www.fda.gov/ForPatients/ucm410359.htm#I-1", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":"Phase IV Clinical Trials (Post marketing)", "Alt_Source2":"NETS Map", "Alt_Description2":"Phase IV studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use. These studies are a form of pharmacovigilance, or surveillance of a drug's safety.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/phase_iv", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":95, "parent":96, "color":"#07534d", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1173, "submap_id":2, "object_id":96, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Post Marketing", "label_name":"Post Marketing", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Genetic Alliance", "Level_II_Description":"Post marketing (also known as Phase IV) studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use. These studies are a form of pharmacovigilance, or surveillance of a drug's safety.", "Level_II_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/phase_iv", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":96, "parent":116, "color":"#07534d", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1174, "submap_id":2, "object_id":97, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":94, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Reanalysis of Premarket Data", "label_name":"Premarket Data Reanalysis", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"C0683944", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCATS", "Level_II_Description":"Reanalysis of prepared data is sometimes referred to as \"Secondary Analysis\" involves the use of existing data, collected for the purposes of a prior study, in order to pursue a research interest which is distinct from that of the original work; this may be a new research question or an alternative perspective on the original question", "Level_II_Link":"http://sru.soc.surrey.ac.uk/SRU22.html", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":97, "parent":94, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1175, "submap_id":2, "object_id":98, "function":"List", "sub_function":null, "relationship":null, "submap_node_parent_id":94, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Spontaneous Reporting", "label_name":"Spontaneous Reporting", "group_name":"Post Marketing", "reference_synonym":"Spontaneous Report", "identifier_CUI":"C2348402", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NCI", "Level_II_Description":"Unsolicited report received by surveillance system via either the voluntary or mandatory route.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA", "Alt_Identifier_CUI":"FDA", "Level_II_Alt_Description":"Spontaneous (i.e. voluntary) reporting refers to information submitted to the FDA and to manufacturers regarding adverse events, medical errors, and product quality problems observed during the use of a drug or biologic. The FDA analyzes both voluntary and mandatory reports to develop hypotheses about possible adverse events of drugs.", "Level_II_alt_Link":"https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm179586.htm", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":98, "parent":94, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1176, "submap_id":2, "object_id":99, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":94, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Pharmaco-Epidemiological Observational Studies", "label_name":"Epidemio - logical Observational Studies", "group_name":"Post Marketing", "reference_synonym":"Observational study", "identifier_CUI":"C3658316", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"MSH", "Level_II_Description":"Works about clinical studies in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study).", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"ClinicalTrials.gov Glossary", "Alt_Identifier_CUI":"ClinicalTrials.gov Glossary", "Level_II_Alt_Description":"A type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific interventions/treatment.", "Level_II_alt_Link":"https://clinicaltrials.gov/ct2/about-studies/glossary", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":99, "parent":94, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1177, "submap_id":2, "object_id":100, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":94, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Pragmatic Safety & Effectiveness Trials", "label_name":"Pragmatic Trials", "group_name":"Post Marketing", "reference_synonym":"Product Surveillance, Post marketing", "identifier_CUI":"C0033267", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"MSH", "Level_II_Description":"Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NIH Collaboratory", "Alt_Identifier_CUI":"NIH Collaboratory", "Level_II_Alt_Description":"Pragmatic clinical trials are performed in real-world clinical settings with highly generalizable populations to generate actionable clinical evidence at a fraction of the typical cost and time needed to conduct a traditional clinical trial. They present an opportunity to efficiently address critical knowledge gaps and generate high-quality evidence to inform medical decision-making.", "Level_II_alt_Link":"http://rethinkingclinicaltrials.org/", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":100, "parent":94, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1178, "submap_id":2, "object_id":101, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Extend Label to Related Drugs", "label_name":"Extend Label to Related Drugs", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"FDA", "Level_II_Description":"Patent Term Restoration Act (Public Law 98-417) to extend patent life to compensate patent holders for marketing time lost while developing the product and awaiting government approval. In 1984 Congress enacted Title II of the Drug Price Competition and  Title II of the Act created a program whereby patent holders whose patents claim a human drug product, medical device, food additive or color additive could recoup some of the lost patent time.", "Level_II_Link":"https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/small-business-assistance-frequently-asked-questions-patent-term-restoration-program", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":101, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1179, "submap_id":2, "object_id":102, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"New Indication/Repurposing", "label_name":"New Indication / Repurposing", "group_name":"Post Marketing", "reference_synonym":"New indication", "identifier_CUI":"C2936405", "NCI_thesaurus_code":null, "semantic_type":"Therapeutic or Preventive Procedure; T061", "sematic_type_code":"T061", "Level_II_Source":"MSH", "Level_II_Description":"The deliberate and methodical practice of finding new applications for existing drugs.", "Level_II_Link":null, "Level_II_Synonym":"Drug Repositioning", "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"After a drug has been on the market for some time, new well-documented uses may emerge and be added to the drug's prescribing information as an FDA-approved indication.", "Level_II_alt_Link":"http://www.geneticalliance.org/programs/biotrust/NETS/content/indication", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Discovering New Therapeutic Uses for Existing Molecules Program", "NCATS_Program_1_Label":"Drug Repurposing Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/ntu", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":102, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1180, "submap_id":2, "object_id":104, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Additional Studies", "label_name":"Additional Studies", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"Studies and clinical trials that sponsors conduct after approval to gather additional information about a product's safety, efficacy, or optimal use. Some of the studies and clinical trials may be required; others may be studies or clinical trials a sponsor has committed to conduct.", "Level_II_Link":"https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":104, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1181, "submap_id":2, "object_id":105, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"FDA Review Label Change", "label_name":"FDA Review Label Change", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"FDA", "Level_II_Description":"FDA to require certain drug and biological product application holders to make safety-related labeling changes based on new safety information that becomes available after approval of the drug or biological product", "Level_II_Link":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-labeling-changes-implementation-section-505o4-federal-food-drug-and-cosmetic-act", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":105, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1182, "submap_id":2, "object_id":106, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Post Marketing Commitments/Requirements", "label_name":"Post Marketing Requirements", "group_name":"Post Marketing", "reference_synonym":"Post marketing clinical trials", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Regulation or Law; T089", "sematic_type_code":"T089", "Level_II_Source":"CUI wo Def", "Level_II_Description":"Post-market requirement and commitment studies and clinical trials occur after a drug or biological product has been approved by FDA.Â ", "Level_II_Link":"https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/ucm064436.htm", "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA", "Alt_Identifier_CUI":"FDA", "Level_II_Alt_Description":"Post marketing study commitments are studies required of or agreed to by a sponsor that are conducted after FDA has approved a product for marketing. FDA uses post marketing study commitments to gather additional information about a product's safety, efficacy, or optimal use. Agreements with sponsors to conduct post marketing studies can be reached either before or after FDA has granted approval to a sponsor to market a product.", "Level_II_alt_Link":"https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/Phase4Trials/default.htm", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":106, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1183, "submap_id":2, "object_id":107, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Off Label Use", "label_name":"Off Label Use", "group_name":"Post Marketing", "reference_synonym":"Off-Label Treatment", "identifier_CUI":"C1096117", "NCI_thesaurus_code":null, "semantic_type":"Injury or Poisoning; T037", "sematic_type_code":"T037", "Level_II_Source":"NCI", "Level_II_Description":"The use of an FDA-approved device, drug, or treatment for a purpose other than that for which it was approved.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA Glossary of Terms: For Patients", "Alt_Identifier_CUI":"FDA Glossary of Terms: For Patients", "Level_II_Alt_Description":"Also called unapproved use of an approved product, off-label use is when your healthcare provider uses an FDA-approved medical product for a use that has not been studied yet.", "Level_II_alt_Link":"https://www.fda.gov/ForPatients/ucm410359.htm#I-1", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":107, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1184, "submap_id":2, "object_id":108, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"FDA Review Post Marketing", "label_name":"FDA Review Post Marketing", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"FDA", "Level_II_Description":"Postmarked requirement and commitment studies and clinical trials occur after a drug or biological product has been approved by FDA.  \nPost marketing studies or clinical trials to demonstrate clinical benefit for drugs approved under the accelerated approval requirements in 21 CFR 314.510 and 21 CFR 601.41\nDeferred pediatric studies (21 CFR 314.55(b) and 601.27(b)), where studies are required under the Pediatric Research Equity Act (PREA)\nStudies or clinical trials to demonstrate safety and efficacy in humans that must be conducted at the time of use of products approved under the Animal Efficacy Rule (21 CFR 314.610(b)(1) and 601.91(b)(1))\nAssess a known serious risk related to the use of the drug\nAssess signals of serious risk related to the use of the drug\nIdentify an unexpected serious risk when available data indicate the potential for a serious risk", "Level_II_Link":"https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":108, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1185, "submap_id":2, "object_id":109, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":95, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Changed Drug Label", "label_name":"Changed Drug Label", "group_name":"Post Marketing", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Regulation or Law; T089", "sematic_type_code":"T089", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"The FDA approved label is the official description of a drug product which includes indication (what the drug is used for); who should take it; adverse events (side effects); instructions for uses in pregnancy, children, and other populations; and safety information for the patient. Labels are often found inside drug product packaging.", "Level_II_Link":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":109, "parent":95, "color":"#07534d", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1186, "submap_id":2, "object_id":110, "function":"List", "sub_function":"Database Reference", "relationship":"Database Reference", "submap_node_parent_id":120, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Usual Customary and Reasonable (UCR)", "label_name":"Usual Customary and Reasonable (UCR)", "group_name":"Medical Landscape", "reference_synonym":"Charges", "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Health Care Activity; T058", "sematic_type_code":"T058", "Level_II_Source":"Medical Billing and Coding Online", "Level_II_Description":"The UCR is the amount of money stipulated in a contract that an insurance company agrees to pay for healthcare costs. After passing the UCR a patient is typically responsible for covering their healthcare costs.", "Level_II_Link":"https://www.medicalbillingandcodingonline.com/medical-billing-terminology/", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":110, "parent":120, "color":"#174da3", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1187, "submap_id":2, "object_id":111, "function":"Process", "sub_function":"Child", "relationship":"Child", "submap_node_parent_id":110, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Insurance Coverage Verification", "label_name":"Insurance Coverage Verification", "group_name":"Medical Landscape", "reference_synonym":"ICD-10", "identifier_CUI":"C1137110", "NCI_thesaurus_code":null, "semantic_type":"Intellectual Product; T170", "sematic_type_code":"T170", "Level_II_Source":"NCI", "Level_II_Description":"The tenth version of the International Classification of Diseases (ICD), published by the World Health Organization in 1992.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":111, "parent":110, "color":"#174da3", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1188, "submap_id":2, "object_id":112, "function":"Process", "sub_function":"Child", "relationship":"Child", "submap_node_parent_id":113, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Incorporation into Clinical Practice", "label_name":"Incorporation into Clinical Practice", "group_name":"Medical Landscape", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":null, "sematic_type_code":null, "Level_II_Source":"NCATS", "Level_II_Description":"Integration of different information, procedures, education in the  practice of medicine", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":112, "parent":113, "color":"#174da3", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1189, "submap_id":2, "object_id":113, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":120, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Access to Therapies", "label_name":"Access to Therapies", "group_name":"Medical Landscape", "reference_synonym":"Health Services Accessibility", "identifier_CUI":"C0018748", "NCI_thesaurus_code":null, "semantic_type":"Functional Concept; T169", "sematic_type_code":"T169", "Level_II_Source":"NCI", "Level_II_Description":"The ability of individuals or a population to utilize and obtain care from the health care system.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"NETS Map", "Alt_Identifier_CUI":"NETS Map", "Level_II_Alt_Description":"Accessible therapies available to all individuals who can benefit from them, including individuals that are uninsured or unable to afford the therapy. Many pharmaceutical companies and disease advocacy organizations provide resources to help make therapies accessible to all individuals who would benefit from treatment.", "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":113, "parent":120, "color":"#174da3", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1190, "submap_id":2, "object_id":114, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":113, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Standard of Care", "label_name":"Standard of Care", "group_name":"Medical Landscape", "reference_synonym":"Standard of Care", "identifier_CUI":"C2936643", "NCI_thesaurus_code":null, "semantic_type":"Therapeutic or Preventive Procedure; T061", "sematic_type_code":"T061", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":"FDA Glossary of Terms: For Patients", "Alt_Identifier_CUI":"FDA Glossary of Terms: For Patients", "Level_II_Alt_Description":"The treatment that medical professionals consider at the time of the study to be the most prevalent and best available treatment.", "Level_II_alt_Link":"https://www.fda.gov/ForPatients/ucm410359.htm#I-1", "Alt_Synonym2":null, "Alt_Source2":"NETS Map", "Alt_Description2":"Standard of care is the consensus among medical professionals on the proper use of the new drug and treatment of patients.", "Alt_URL2":"http://www.geneticalliance.org/programs/biotrust/NETS/content/care", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":114, "parent":113, "color":"#174da3", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1192, "submap_id":2, "object_id":116, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":null, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Small Molecule Map", "label_name":"Small Molecule Map", "group_name":"Translation Science", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":null, "sematic_type_code":null, "Level_II_Source":"NCATS", "Level_II_Description":"The small molecule map provides dynamic representations of the modern therapeutic development process to more easily identify inefficiencies and integrate efforts to expedite new therapies for patients.Â  Small molecule drugs are chemically manufactured compounds of relatively low molecular size that make up the vast majority of drugs on the market today.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":116, "parent":{"class":"NaN"}, "color":"#7b1fa2", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1193, "submap_id":2, "object_id":118, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":134, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"GLP Preclinical Studies", "label_name":"GLP Preclinical Studies", "group_name":"Lead Optimization", "reference_synonym":"Preclinical", "identifier_CUI":"C1709630", "NCI_thesaurus_code":null, "semantic_type":"Qualitative Concept; T080", "sematic_type_code":"T080", "Level_II_Source":"NCI", "Level_II_Description":"Refers to in vitro testing or in vivo animal testing before clinical trials in humans are to be carried out.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":118, "parent":134, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1194, "submap_id":2, "object_id":119, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Clinical Research", "label_name":"Clinical Research", "group_name":"Clinical Research", "reference_synonym":"Clinical Research and Development", "identifier_CUI":"C0008972", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"NCI", "Level_II_Description":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":119, "parent":116, "color":"#028475", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1195, "submap_id":2, "object_id":120, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":116, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Medical Landscape", "label_name":"Medical Landscape", "group_name":"Medical Landscape", "reference_synonym":null, "identifier_CUI":"C0025100", "NCI_thesaurus_code":null, "semantic_type":"Professional or Occupational Group; T097", "sematic_type_code":"T097", "Level_II_Source":"MSH", "Level_II_Description":"Individuals professionally qualified in the management of patients' records. Duties may include planning, designing, and managing systems for patient administrative and clinical data, as well as patient medical records. The concept includes medical record technicians.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":120, "parent":116, "color":"#174da3", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1196, "submap_id":2, "object_id":134, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":35, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Short List for Preclinical Candidates", "label_name":"Preclinical Candidates (Short List)", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":null, "Level_II_Description":"Pending Priority", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":134, "parent":35, "color":"#517482", "nodeLocContent":[], "category":"parent", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1198, "submap_id":2, "object_id":713, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":90, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"NDA or BLA Regulatory Review Complete", "label_name":"NDA or BLA Regulatory Review Complete", "group_name":"Regulatory Review", "reference_synonym":"FDA review", "identifier_CUI":"C3242240", "NCI_thesaurus_code":null, "semantic_type":"Idea or Concept; T078", "sematic_type_code":"T078", "Level_II_Source":"FDA Glossary of Terms", "Level_II_Description":"A review is the basis of FDA's decision to approve an application. It is a comprehensive analysis of clinical trial data and other information prepared by FDA drug application reviewers. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology", "Level_II_Link":"https://www.fda.gov/drugs/informationondrugs/ucm079436.htm#R", "Level_II_Synonym":null, "Level_II_Alt_Source":"Drugs@FDA Glossary", "Alt_Identifier_CUI":"Drugs@FDA Glossary", "Level_II_Alt_Description":"A review is the basis of FDA's decision to approve an application. It is a comprehensive analysis of clinical trial data and other information prepared by FDA drug application reviewers. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology.", "Level_II_alt_Link":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page", "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":713, "parent":90, "color":"#477700", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1199, "submap_id":2, "object_id":1033, "function":"Process", "sub_function":null, "relationship":null, "submap_node_parent_id":36, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 0 ]}, "loc_coordinates":null, "name":"Lead Candidate Optimization Biologics", "label_name":"Lead Candidate Optimization Biologics", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Research Activity; T062", "sematic_type_code":"T062", "Level_II_Source":"Nature.com", "Level_II_Description":"Lead optimization is the process by which a drug candidate is designed after an initial lead compound is identified. The process involves iterative rounds of synthesis and characterization of a potential drug to build up a picture of how chemical structure and activity are related in terms of interactions with its targets and its metabolism.", "Level_II_Link":"https://www.nature.com/subjects/lead-optimization", "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":"GSK Glossary", "Alt_Description2":"Process in which the drug-like properties of an initial lead or lead series are improved. Typically, biological activity will be enhanced, in vivo efficacy will be demonstrated and compounds with a physicochemical, pharmacological and toxicological profile consistent with progression to the clinic will be identified.", "Alt_URL2":"http://www.dpac.gsk.com/glossary.html", "NCATS_Program_1":null, "NCATS_Program_1_Label":null, "NCATS_Program_Link_1":null, "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":1033, "parent":36, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false},
{"submap_nodes_id":1200, "submap_id":2, "object_id":1034, "function":"Document", "sub_function":null, "relationship":null, "submap_node_parent_id":35, "submap_show":{"type":"Buffer", "data":[ 1 ]}, "submap_simple_show":{"type":"Buffer", "data":[ 1 ]}, "loc_coordinates":null, "name":"Candidate Compounds Biologics", "label_name":"Candidate Compounds (B)", "group_name":"Lead Optimization", "reference_synonym":null, "identifier_CUI":"Alternate Source", "NCI_thesaurus_code":null, "semantic_type":"Laboratory Procedure; T059", "sematic_type_code":"T059", "Level_II_Source":"NCATS", "Level_II_Description":"Candidate compounds are former lead compounds that have sufficiently advanced through preclinical studies including medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics. Candidate compounds must go through additional testing in whole organisms to measure compound efficacy and toxicology before it can be submitted to the FDA as part of an Investigational New Drug (IND) application to begin first-in-human clinical trials.", "Level_II_Link":null, "Level_II_Synonym":null, "Level_II_Alt_Source":null, "Alt_Identifier_CUI":null, "Level_II_Alt_Description":null, "Level_II_alt_Link":null, "Alt_Synonym2":null, "Alt_Source2":null, "Alt_Description2":null, "Alt_URL2":null, "NCATS_Program_1":"Therapeutics for Rare and Neglected Diseases (TRND) Program", "NCATS_Program_1_Label":"Rare Disease Therapeutics Program", "NCATS_Program_Link_1":"https://ncats.nih.gov/trnd", "NCATS_Program_2":null, "NCATS_Program_2_Label":null, "NCATS_Program_Link_2":null, "NCATS_Program_3":null, "NCATS_Program_3_Label":null, "NCATS_Program_Link_3":null, "bottleneck":null, "key":1034, "parent":35, "color":"#517482", "nodeLocContent":[], "category":"", "inDirections":false, "isStartPoint":false, "isEndPoint":false, "hasLocContent":false}
 ],
  "linkDataArray": [
{"from":116, "to":1, "category":"parentChild"},
{"from":1, "to":3, "category":"parentChild"},
{"from":1, "to":4, "category":"parentChild"},
{"from":1, "to":5, "category":"parentChild"},
{"from":1, "to":6, "category":"parentChild"},
{"from":3, "to":7, "category":"parentChild"},
{"from":5, "to":8, "category":"parentChild"},
{"from":5, "to":9, "category":"parentChild"},
{"from":5, "to":10, "category":"parentChild"},
{"from":1, "to":11, "category":"parentChild"},
{"from":11, "to":12, "category":"parentChild"},
{"from":11, "to":13, "category":"parentChild"},
{"from":1, "to":14, "category":"parentChild"},
{"from":116, "to":15, "category":"parentChild"},
{"from":19, "to":16, "category":"parentChild"},
{"from":15, "to":19, "category":"parentChild"},
{"from":19, "to":21, "category":"parentChild"},
{"from":19, "to":22, "category":"parentChild"},
{"from":15, "to":23, "category":"parentChild"},
{"from":23, "to":24, "category":"parentChild"},
{"from":23, "to":25, "category":"parentChild"},
{"from":116, "to":26, "category":"parentChild"},
{"from":26, "to":27, "category":"parentChild"},
{"from":27, "to":28, "category":"parentChild"},
{"from":31, "to":29, "category":"parentChild"},
{"from":31, "to":30, "category":"parentChild"},
{"from":26, "to":31, "category":"parentChild"},
{"from":31, "to":32, "category":"parentChild"},
{"from":31, "to":33, "category":"parentChild"},
{"from":31, "to":34, "category":"parentChild"},
{"from":116, "to":35, "category":"parentChild"},
{"from":35, "to":36, "category":"parentChild"},
{"from":36, "to":37, "category":"parentChild"},
{"from":36, "to":38, "category":"parentChild"},
{"from":36, "to":39, "category":"parentChild"},
{"from":36, "to":40, "category":"parentChild"},
{"from":36, "to":41, "category":"parentChild"},
{"from":36, "to":42, "category":"parentChild"},
{"from":35, "to":43, "category":"parentChild"},
{"from":43, "to":44, "category":"parentChild"},
{"from":43, "to":45, "category":"parentChild"},
{"from":43, "to":46, "category":"parentChild"},
{"from":43, "to":47, "category":"parentChild"},
{"from":43, "to":48, "category":"parentChild"},
{"from":43, "to":49, "category":"parentChild"},
{"from":134, "to":50, "category":"parentChild"},
{"from":134, "to":51, "category":"parentChild"},
{"from":134, "to":52, "category":"parentChild"},
{"from":134, "to":53, "category":"parentChild"},
{"from":134, "to":54, "category":"parentChild"},
{"from":134, "to":55, "category":"parentChild"},
{"from":134, "to":56, "category":"parentChild"},
{"from":77, "to":57, "category":"parentChild"},
{"from":61, "to":58, "category":"parentChild"},
{"from":61, "to":59, "category":"parentChild"},
{"from":61, "to":60, "category":"parentChild"},
{"from":119, "to":61, "category":"parentChild"},
{"from":61, "to":62, "category":"parentChild"},
{"from":119, "to":63, "category":"parentChild"},
{"from":65, "to":64, "category":"parentChild"},
{"from":119, "to":65, "category":"parentChild"},
{"from":65, "to":66, "category":"parentChild"},
{"from":61, "to":67, "category":"parentChild"},
{"from":61, "to":68, "category":"parentChild"},
{"from":63, "to":69, "category":"parentChild"},
{"from":83, "to":70, "category":"parentChild"},
{"from":77, "to":71, "category":"parentChild"},
{"from":77, "to":72, "category":"parentChild"},
{"from":63, "to":73, "category":"parentChild"},
{"from":77, "to":74, "category":"parentChild"},
{"from":63, "to":75, "category":"parentChild"},
{"from":119, "to":76, "category":"parentChild"},
{"from":119, "to":77, "category":"parentChild"},
{"from":76, "to":78, "category":"parentChild"},
{"from":76, "to":79, "category":"parentChild"},
{"from":76, "to":80, "category":"parentChild"},
{"from":119, "to":81, "category":"parentChild"},
{"from":81, "to":82, "category":"parentChild"},
{"from":119, "to":83, "category":"parentChild"},
{"from":83, "to":84, "category":"parentChild"},
{"from":76, "to":85, "category":"parentChild"},
{"from":116, "to":86, "category":"parentChild"},
{"from":86, "to":87, "category":"parentChild"},
{"from":87, "to":88, "category":"parentChild"},
{"from":87, "to":89, "category":"parentChild"},
{"from":86, "to":90, "category":"parentChild"},
{"from":90, "to":92, "category":"parentChild"},
{"from":90, "to":93, "category":"parentChild"},
{"from":96, "to":94, "category":"parentChild"},
{"from":96, "to":95, "category":"parentChild"},
{"from":116, "to":96, "category":"parentChild"},
{"from":94, "to":97, "category":"parentChild"},
{"from":94, "to":98, "category":"parentChild"},
{"from":94, "to":99, "category":"parentChild"},
{"from":94, "to":100, "category":"parentChild"},
{"from":95, "to":101, "category":"parentChild"},
{"from":95, "to":102, "category":"parentChild"},
{"from":95, "to":104, "category":"parentChild"},
{"from":95, "to":105, "category":"parentChild"},
{"from":95, "to":106, "category":"parentChild"},
{"from":95, "to":107, "category":"parentChild"},
{"from":95, "to":108, "category":"parentChild"},
{"from":95, "to":109, "category":"parentChild"},
{"from":120, "to":110, "category":"parentChild"},
{"from":110, "to":111, "category":"parentChild"},
{"from":113, "to":112, "category":"parentChild"},
{"from":120, "to":113, "category":"parentChild"},
{"from":113, "to":114, "category":"parentChild"},
{"from":134, "to":118, "category":"parentChild"},
{"from":116, "to":119, "category":"parentChild"},
{"from":116, "to":120, "category":"parentChild"},
{"from":35, "to":134, "category":"parentChild"},
{"from":90, "to":713, "category":"parentChild"},
{"from":36, "to":1033, "category":"parentChild"},
{"from":35, "to":1034, "category":"parentChild"},
{"from":3, "to":4, "category":"linkType"},
{"from":4, "to":3, "category":"linkType"},
{"from":4, "to":5, "category":"linkType"},
{"from":5, "to":10, "category":"linkType"},
{"from":5, "to":8, "category":"linkType"},
{"from":5, "to":6, "category":"linkType"},
{"from":5, "to":4, "category":"linkType"},
{"from":5, "to":27, "category":"linkType"},
{"from":5, "to":19, "category":"linkType"},
{"from":6, "to":27, "category":"linkType"},
{"from":7, "to":11, "category":"linkType"},
{"from":7, "to":3, "category":"linkType"},
{"from":8, "to":5, "category":"linkType"},
{"from":9, "to":5, "category":"linkType"},
{"from":9, "to":10, "category":"linkType"},
{"from":10, "to":5, "category":"linkType"},
{"from":10, "to":9, "category":"linkType"},
{"from":12, "to":13, "category":"linkType"},
{"from":12, "to":11, "category":"linkType"},
{"from":12, "to":9, "category":"linkType"},
{"from":13, "to":12, "category":"linkType"},
{"from":13, "to":66, "category":"linkType"},
{"from":14, "to":11, "category":"linkType"},
{"from":19, "to":22, "category":"linkType"},
{"from":19, "to":21, "category":"linkType"},
{"from":21, "to":23, "category":"linkType"},
{"from":22, "to":23, "category":"linkType"},
{"from":23, "to":24, "category":"linkType"},
{"from":23, "to":25, "category":"linkType"},
{"from":24, "to":61, "category":"linkType"},
{"from":25, "to":61, "category":"linkType"},
{"from":27, "to":28, "category":"linkType"},
{"from":28, "to":31, "category":"linkType"},
{"from":29, "to":31, "category":"linkType"},
{"from":30, "to":31, "category":"linkType"},
{"from":31, "to":32, "category":"linkType"},
{"from":31, "to":34, "category":"linkType"},
{"from":31, "to":33, "category":"linkType"},
{"from":32, "to":29, "category":"linkType"},
{"from":32, "to":27, "category":"linkType"},
{"from":33, "to":34, "category":"linkType"},
{"from":34, "to":36, "category":"linkType"},
{"from":36, "to":38, "category":"linkType"},
{"from":37, "to":39, "category":"linkType"},
{"from":38, "to":87, "category":"linkType"},
{"from":38, "to":37, "category":"linkType"},
{"from":39, "to":37, "category":"linkType"},
{"from":39, "to":40, "category":"linkType"},
{"from":39, "to":41, "category":"linkType"},
{"from":40, "to":39, "category":"linkType"},
{"from":40, "to":42, "category":"linkType"},
{"from":41, "to":39, "category":"linkType"},
{"from":41, "to":42, "category":"linkType"},
{"from":42, "to":40, "category":"linkType"},
{"from":42, "to":41, "category":"linkType"},
{"from":42, "to":43, "category":"linkType"},
{"from":43, "to":44, "category":"linkType"},
{"from":44, "to":45, "category":"linkType"},
{"from":44, "to":46, "category":"linkType"},
{"from":45, "to":47, "category":"linkType"},
{"from":46, "to":48, "category":"linkType"},
{"from":47, "to":49, "category":"linkType"},
{"from":48, "to":49, "category":"linkType"},
{"from":49, "to":134, "category":"linkType"},
{"from":50, "to":118, "category":"linkType"},
{"from":51, "to":87, "category":"linkType"},
{"from":51, "to":54, "category":"linkType"},
{"from":52, "to":87, "category":"linkType"},
{"from":52, "to":54, "category":"linkType"},
{"from":53, "to":87, "category":"linkType"},
{"from":53, "to":54, "category":"linkType"},
{"from":54, "to":87, "category":"linkType"},
{"from":54, "to":55, "category":"linkType"},
{"from":55, "to":56, "category":"linkType"},
{"from":56, "to":55, "category":"linkType"},
{"from":57, "to":14, "category":"linkType"},
{"from":57, "to":11, "category":"linkType"},
{"from":57, "to":71, "category":"linkType"},
{"from":57, "to":3, "category":"linkType"},
{"from":57, "to":58, "category":"linkType"},
{"from":57, "to":60, "category":"linkType"},
{"from":58, "to":59, "category":"linkType"},
{"from":58, "to":57, "category":"linkType"},
{"from":59, "to":61, "category":"linkType"},
{"from":60, "to":57, "category":"linkType"},
{"from":60, "to":61, "category":"linkType"},
{"from":60, "to":59, "category":"linkType"},
{"from":61, "to":62, "category":"linkType"},
{"from":61, "to":68, "category":"linkType"},
{"from":61, "to":67, "category":"linkType"},
{"from":62, "to":83, "category":"linkType"},
{"from":63, "to":64, "category":"linkType"},
{"from":63, "to":65, "category":"linkType"},
{"from":63, "to":77, "category":"linkType"},
{"from":64, "to":14, "category":"linkType"},
{"from":65, "to":66, "category":"linkType"},
{"from":65, "to":67, "category":"linkType"},
{"from":65, "to":68, "category":"linkType"},
{"from":65, "to":61, "category":"linkType"},
{"from":66, "to":13, "category":"linkType"},
{"from":66, "to":11, "category":"linkType"},
{"from":66, "to":65, "category":"linkType"},
{"from":67, "to":69, "category":"linkType"},
{"from":68, "to":69, "category":"linkType"},
{"from":69, "to":70, "category":"linkType"},
{"from":70, "to":83, "category":"linkType"},
{"from":71, "to":72, "category":"linkType"},
{"from":72, "to":73, "category":"linkType"},
{"from":73, "to":74, "category":"linkType"},
{"from":74, "to":75, "category":"linkType"},
{"from":75, "to":63, "category":"linkType"},
{"from":75, "to":74, "category":"linkType"},
{"from":76, "to":79, "category":"linkType"},
{"from":76, "to":78, "category":"linkType"},
{"from":76, "to":80, "category":"linkType"},
{"from":76, "to":81, "category":"linkType"},
{"from":77, "to":76, "category":"linkType"},
{"from":78, "to":81, "category":"linkType"},
{"from":78, "to":79, "category":"linkType"},
{"from":79, "to":81, "category":"linkType"},
{"from":79, "to":80, "category":"linkType"},
{"from":80, "to":81, "category":"linkType"},
{"from":81, "to":82, "category":"linkType"},
{"from":81, "to":90, "category":"linkType"},
{"from":81, "to":88, "category":"linkType"},
{"from":82, "to":83, "category":"linkType"},
{"from":83, "to":84, "category":"linkType"},
{"from":83, "to":70, "category":"linkType"},
{"from":84, "to":87, "category":"linkType"},
{"from":85, "to":76, "category":"linkType"},
{"from":87, "to":88, "category":"linkType"},
{"from":87, "to":72, "category":"linkType"},
{"from":87, "to":77, "category":"linkType"},
{"from":88, "to":90, "category":"linkType"},
{"from":89, "to":90, "category":"linkType"},
{"from":90, "to":91, "category":"linkType"},
{"from":91, "to":93, "category":"linkType"},
{"from":91, "to":92, "category":"linkType"},
{"from":92, "to":85, "category":"linkType"},
{"from":93, "to":94, "category":"linkType"},
{"from":94, "to":100, "category":"linkType"},
{"from":94, "to":98, "category":"linkType"},
{"from":94, "to":99, "category":"linkType"},
{"from":94, "to":95, "category":"linkType"},
{"from":94, "to":97, "category":"linkType"},
{"from":95, "to":4, "category":"linkType"},
{"from":95, "to":102, "category":"linkType"},
{"from":95, "to":101, "category":"linkType"},
{"from":95, "to":105, "category":"linkType"},
{"from":95, "to":103, "category":"linkType"},
{"from":95, "to":104, "category":"linkType"},
{"from":95, "to":110, "category":"linkType"},
{"from":95, "to":107, "category":"linkType"},
{"from":99, "to":100, "category":"linkType"},
{"from":102, "to":4, "category":"linkType"},
{"from":104, "to":108, "category":"linkType"},
{"from":105, "to":109, "category":"linkType"},
{"from":107, "to":110, "category":"linkType"},
{"from":108, "to":106, "category":"linkType"},
{"from":110, "to":111, "category":"linkType"},
{"from":111, "to":112, "category":"linkType"},
{"from":112, "to":113, "category":"linkType"},
{"from":113, "to":114, "category":"linkType"},
{"from":114, "to":115, "category":"linkType"},
{"from":115, "to":65, "category":"linkType"},
{"from":115, "to":5, "category":"linkType"},
{"from":118, "to":51, "category":"linkType"},
{"from":118, "to":52, "category":"linkType"},
{"from":118, "to":53, "category":"linkType"},
{"from":134, "to":50, "category":"linkType"}
 ]}
